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Supplemental Figure 1: Hypothetical model of peripheral blood TCR-transgenic cell 
repopulation. A. Green line: Peripheral blood levels of TCR-transgenic cells as a result of the 
adoptive cell transfer of mature lymphocytes expressing NY-ESO-1 TCR. These cells expand briskly 
over the first two weeks and achieve high peripheral blood levels, followed by a more protracted 
contraction. Dotted green line: Our functional studies demonstrate that these cells lose their initial 
high lytic activity and become immune deviated (shift in cytokine profile upon antigen exposure) but 
still remain antigen-specific effector cells. Red line: TCR-transgenic cells as a result of the 
endogenous re-population of peripheral tissues by TCR-transgenic HSCs will first appear in the 
periphery by 1-3 months and will provide a continuous source of TCR-transgenic cells with maintained 
antitumor functionality. B. Representative analysis of TCR-transgenic T cells by MHC tetramer assay 
in blood from a patient enrolled in the mature TCR-transgenic ACT clinical trial. The initial expansion 
of TCR transgenic cells is followed by a decrease in their frequency over time.  
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Supplemental Figure 2:  GLP team organizational chart. Due to the complexity of this GLP study, 
no single team could provide personnel with all of the specialized skills required. The study was 
undertaken as a collaborative effort among members of the Ribas laboratory and members of the 
Department of Laboratory Animal Medicine (DLAM) in UCLA.  A total of 32 staff were involved in the 
study. The sponsor initiated the study, financially supported it and submitted the IND application to 
the FDA. Test Facility Management (TFM) Liaisons were appointed to oversee the facilities and the 
personnel of each group and facilitate communication with the Study Director and the TFM. The Study 
Director was the central point of control of the study and had overall responsibility for the technical 
conduct of the study, the interpretation, analysis, documentation and reporting of results. An 
independent Quality Assurance Unit inspected the facility and the procedures to ensure GLP 
regulations were followed and also reviewed all documentation and reports generated.  
The solid line indicates personnel reporting structure for this study. The dotted line indicates lines of 
communication. 
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Supplemental Figure 3. Bone marrow transplant (BMT) optimization studies in HLA-A2/Kb 
transgenic mice. A. Mice were untreated or received an irradiation dose of 500, 700 or 900cGy 
respectively. Mice were followed for 30 days. Kaplan-Meier survival curves after irradiation (n= 3-6). 
B. Lin- cells were purified from the bone marrow of HLA-A2/Kb donor mice, and either prestimulated 
for 18-20h, transduced with the LV-NY-ESO-1 TCR/sr39TK and cultured for 24h more (short culture) 
or prestimulated for 48 hours, transduced with the same vector and cultured for 48 hours more (long 
culture). T cells were purified from the spleen of HLA-A2/Kb donor mice, activated for 16h, transduced 
with RV-NY-ESO-1 TCR and expanded for 3 days. 1.5million Lin- cells and 2 million T cells were co-
administered to HLA-A2/Kb mice that had previously received TBI (900cGy). Mice were followed for 
3 months. Kaplan-Meier survival curve after BMT with long culture Lin- cells (left) and short culture 
Lin- cells (right), (n=4-5). C. Short culture Lin- cell dose escalation. Two, 1.5, 1.0, 0.5 or 0.2 million 
short culture Lin- cells transduced with the LV-NY-ESO-1 TCR/sr39TK were co-administered with 2 
million T cells transduced with the RV-NY-ESO-1 TCR to myelodepleted HLA-A2/Kb mice. Mice were 
followed for 3 months. Kaplan-Meier survival curve. Data for the 1.5 million Lin- cohort is in figure 
S3B (right), (n=4-5). D. T cell VCN dose escalation. 1.5 million short culture Lin- cells transduced with 
the LV-NY-ESO-1 TCR/sr39TK were co-administered with 2 million T cells transduced with 
decreasing amounts of the RV-NY-ESO-1 TCR to myelodepleted HLA-A2/Kb mice. The retrovirus 
VCN in the T cells is indicated in the figure. Mice were followed for 3 months. Kaplan-Meier survival 
curve, (n=5).   
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Supplemental Figure 4. Body weight and hematology assessment at day 5 and 3 months after 
BMT. TCR-engineered Lin- cells and T cells were co-administered in myelodepleted HLA-A2/Kb mice. 
Mice were followed for three months after BMT, and total body weight was measured 2-3 times a 
week. Body weight was divided by gender. A. Female (n=8). B. Male (n=8). * p<0.05 vs cohort A pair-
wise comparisons of least-squares means in a linear model framework with Tukey-Kramer 
adjustment within each time point, considered significant only if 5 or more consecutive measurements 
were significant. C. Hematology at 5 days (n=6) and 3 months (n=12-15) after BMT. HCT, hematocrit; 
MCH, mean corpuscular hemoglobin; RDW, red cell distribution width; MPV, mean platelet volume; 
MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration. Mean ±SEM 
is plotted. * p<0.05 vs cohort A, ^ p<0.05 vs cohort C, # p<0.05 vs Cohort E, pair-wise comparisons 
of least-squares means in a linear model framework with Tukey-Kramer adjustment within each time 
point.  
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Supplemental Figure 5. Spleen and bone marrow cellularity at day 5 and 3 months after BMT. 
TCR-engineered Lin- cells and T cells were co-administered in myelodepleted HLA-A2/Kb mice. Mice 
were followed for three months after BMT. Mice from each cohort were euthanized at day 5 (n=6) and 
3 months (n=12-15) after BMT. A. Splenocyte counts at 5 days. B. Bone marrow cell counts at 5 days 
and 3 months after BMT. C. Spleen weight at 5 days and 3 months after BMT. Mean ±SEM is plotted.  
* p<0.05 vs cohort A, pair-wise comparisons of least-squares means in a linear model framework with 
Tukey-Kramer adjustment within each time point. 
 
  
  
Supplemental Figure 6. Serum chemistry at 3 months after BMT. TCR-engineered Lin- cells and 
T cells were co-administered in myelodepleted HLA-A2/Kb mice. A. Mice were followed for 3 months 
after BMT (n=12-15). TBIL, total bilirubin; BUN, blood urea nitrogen; Gluc, glucose; Glob, globulin; 
A/G, albumin to globulin ratio; TP, total protein. * p<0.05 vs cohort A, pair-wise comparisons of least-
squares means in a linear model framework with Tukey-Kramer adjustment. 
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Supplemental Figure 7. Flow cytometry gating strategy for bone marrow and splenocytes 
phenotype characterization. TCR-engineered Lin- cells and T cells were co-administered in 
myelodepleted HLA-A2/Kb mice. At 3 months after BMT phenotype characterization of the bone 
marrow cells and the splenocytes was performed. Gating strategy is shown. A. The lineage-negative 
(Lin-) cell population was gated on the total bone marrow single cells. LSK population was measured 
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by gating the ScaI+ c-kit+ cells in the Lin- population. The hematopoietic stem cell population (HSC) 
was gated on the CD48- CD150+ LSK population. B. The Lin-, LSK and HSC populations were also 
measured in the Vβ13+ bone marrow single cells. C. The CD3+ population was gated on the 
splenocyte single cells population. The CD4+, CD8+ and NKT (CD3+ NK1.1+) cells were gated on the 
CD3+ population. D. Same gating strategy as in C was applied to the total Vβ13+ splenocyte single 
cell population. E. Granulocytes (Gr1+), neutrophils (Gr+, CD11bhi), macrophages-monocytes 
(CD11b+ F4-80+) and B cells (IgM+ B220+) were gated on the splenocyte single cell population. F. 
The same gates as in E were applied to the Vβ13+ splenocyte single cell population.    
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Supplemental Figure 8. Survival and hematology 3 months after BMT with Lin- cells 
transduced with LV-empty, LV-NY-ESO-1 TCR or LV-NY-ESO-1 TCR/sr39TK. TCR-engineered 
Lin- cells transduced with LV-NYESO-1 TCR/sr39TK, LV-NYESO-1 TCR or empty vector were 
transplanted in myelodepleted HLA-A2/Kb mice. Mice were followed for 3 months after BMT. A. 
Kaplan-Meier survival curve. No significant differences by Log-rank test comparing median survival 
among the different treatment groups (p=0.3858, n=6-9). B. White Blood Cell differential at 3 months 
after BMT in percentages (n=5-9). Neut, neutrophils; Lymphs, lymphocytes; Mono, monocytes; Eos, 
eosinophils; Baso, basophils. No significant differences were observed by Pair-wise Comparison with 
Tukey-Kramer adjustment. 
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Supplemental Figure 9. Differentiation of NYESO TCR/sr39TK-engineered T cells in ATOs 
(artificial thymic organoids). Fresh CD34+ cells were enriched using CliniMACS. CD34+CD3- cells 
were purified by FACS sorting. CD34+CD3-were transduced with LV-NYESO TCR/sr39TK or mock-
transduced (no virus added) and cultured in ATOs for the indicated times. Analysis shows total ATO 
cells (top row) gated on DAPI-CD14-CD56-mCD29- cells (to gate out dead cells, 
monocytes/macrophages, NK cells, and murine stromal cells, respectively). Sequential gates are 
shown by arrows. CD3+TCRab+CD8SP T cells expressing NY-ESO-1 TCR (1G4 clone) are indicated 
by the Vβ13+ dextramer+ gate. 
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Supplemental Table 1. Certificate of Analysis of the GMP-comparable LV-NY-ESO-1 
TCR/sr39TK (RRL-MSCV-optNYESO-optsr39TK-WPRE, production volume: 20L). 
 
TEST METHOD ACCEPTABILITY 
CRITERIA 
RESULTS 
Physical viral 
vector titer 
P24 ELISA Report results 3.9 x 107 pg/mL 
Infectious titer 
 
Assay using HT29 cells Report results 6.8 x 108 ifu/mL 
Sterility Aerobic and anaerobic 
culture for bacteria and 
fungus 
No growth within 14 
days 
No growth within 14 
days 
Mycoplasma  Culture and Vero 
indicator cells 
Negative Negative 
Endotoxin Limulus amebocyte 
lysate 
<100 EU/mL per 
sample 
<0.06 EU/mL 
 
EU, endotoxin units; Ifu, infectious units 
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Supplemental Table 2. Certificate of Analysis of the Clinical Grade Lentivirus LV-NY-ESO-
1 TCR/sr39TK (RRL-MSCV-optNYESO-optsr39TK-WPRE, production volume 60L). 
 
TEST METHOD ACCEPTABILITY 
CRITERIA 
RESULTS 
Vector insert Southern Blot analysis Vector size 
consistent with 
predicted fragment 
size 
Vector size consistent 
with predicted 
fragment size 
Physical viral 
vector titer 
P24 ELISA ≥ 2.5 x 107 pg/mL 4.0 x 107 pg/mL 
Infectious titer 
 
Assay using HT29 cells ≥ 2.0 x 107 ifu/mL 2.0 x 108 ifu/mL 
Sterility Aerobic and anaerobic 
culture for bacterial and 
fungal contamination 
No growth within 14 
days 
No growth within 14 
days 
Mycoplasma 
contamination 
Culture and Vero 
indicator cells 
Negative Negative 
In vitro viral 
assay 
Assay on MRC-5, Vero 
and A549 cells 
No CPE or 
hemadsorption 
No CPE or 
hemadsorption 
Replication 
competent 
lentivirus 
testing (RCL) 
Co-culture of end 
production cells with 
C8166 cells with 
amplification and 
indicator phases. 
Supernatant testing on 
C8166 cells with 
amplification and 
indicator phases. 
No evidence of RCL No evidence of RCL 
Endotoxin 
concentration 
Limulus amebocyte 
lysate 
<100 EU/ml each 
sample 
>30 and < 48 EU/ml 
Residual total 
viral DNA 
Quantitative PCR 
(qPCR) 
Report result 9.14x105 fg/μL 
Residual 
benzonase 
ELISA Report result Below limit of 
detection  
Transfer of 
residual E1A 
qPCR Negative <10 copies/0.2μg 
DNAa  
Transfer of 
residual SV40 
qPCR Negative <10 copies/0.2μg 
DNAa 
aThe limit of detection for this assay is 10 copies/0.2μg DNA. A result of <10 copies/0.2 μg DNA 
is considered negative. 
EU, endotoxin units; ifu, infectious units; CPE, cytopathic effect; RCL, replication-competent 
lentivirus 
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Supplemental Table 3. Certificate of Analysis of the clinical grade RV-NY-ESO-1 TCR 
(MSGV1-A2aB-1G4A-LY3H10) (Production volume 18L)*. 
 
 
TEST METHOD LIMITS RESULTS 
Sterility Aerobic and anaerobic 
culture for bacterial 
and fungal 
contaminants 
No growth 14 days No growth 14 days 
Mycoplasma 
contamination 
Mycoplasma culture Negative for presence 
of Mycoplasma 
Negative for presence 
of Mycoplasma 
Adventitious 
virus 
contamination 
In-vitro viral assay 
utilizing 3T3, MRC-5 
and Vero cells 
No CPE or 
hemadsorption 
No CPE or 
hemadsorption 
Endotoxin 
concentration 
Limulus amebocyte 
lysate 
< 0.33 EU/mL Harvest 1-6: less than 
0.06 EU/mL 
Replication 
competent 
retrovirus: 
GAL-V 
S+L-(PG-4) 
(293 infection) 5% of 
vector supernatant 
No evidence of RCR No evidence of RCR 
S+L-(PG-4) (293 co- 
culture) 108 cells from 
production run 
No evidence of RCR No evidence of RCR 
Transgene 
expression 
NY-ESO-1157-165 
tetramer or dextramer 
staining in activated 
PBMC 
> 10% NY-ESO-1157-165 
tetramer or dextramer 
positive cells among 
CD3+ T lymphocytes 
41.5% NY-ESO-1157-165 
dextramer positive 
cells among CD3+ T 
lymphocytes 
Potency NY-ESO-1157-165 
peptide and antigen- 
specific IFN-γ 
production by ELISA 
> 30,000 pg/ml of IFN-γ 
production upon NY- 
ESO-1157-165    peptide 
stimulation using NY- 
ESO-1157-165  peptide- 
pulsed K562/A2.1 cells 
> 300,000 pg/ml of 
IFN- γ production upon 
NY-ESO-1157-165  
peptide stimulation 
using NY-ESO-1157-165  
peptide- 
pulsed K562/A2.1 cells 
CPE, cytopathic effect; EU, endotoxin units; PBMCs, peripheral blood mononuclear cells; RCR, 
replication-competent retrovirus 
*Viral vector produced using a PG13 master cell bank (PG13-A2aB-1G4A-LY-3H10 MCB) 
obtained from Dr. Rosenberg. A cross-reference letter was obtained from Dr. Rosenberg in 
support of the IND for this clinical trial.  
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Supplemental Table 4. Certificate of Analysis of the GMP comparable RV-NY-ESO-1 TCR 
(MSGV1-A2ab-1G4A-Ly3H10, Production volume: 3L). 
 
TEST METHOD ACCEPTABILITY 
CRITERIA 
RESULTS 
Sterility Aerobic and anaerobic 
culture for bacterial and 
fungal contaminants 
No growth within 14 
days 
No growth within 14 
days 
Mycoplasma 
contamination 
qPCR  Negative Negative 
Endotoxin Limulus amebocyte 
lysate 
<100 EU/mL  <0.06 EU/mL 
 
EU, endotoxin units  
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Supplemental Table 5. Co-Administration of NY-ESO-1 TCR Genetically Modified T cells 
and Hematopoietic Stem Cells (HSCs) in HLA-A2.1/Kb mice. GLP studies cohort 
distribution. 
 
 a The study was divided into 3 experiments. 1.2 x106 Lin- cells were injected for Experiment 2 
and 1.3 x106 Lin- cells were injected for Experiments 1 and 3. Animals in Experiments 1 and 2 
were euthanized at 3 months after BMT, animals in Experiment 3 were euthanized at day 5 after 
BMT. 
b Mice were sacrificed on two consecutive days (days 87 and 88 after BMT) to accommodate 
scheduling with external test sites and allow enough time to process and ship all samples.  
Mice from Cohort A were not irradiated.   
XRT, Irradiation; BMT, bone marrow transplantation; Lin- cells, Lineage negative; M, Male; F, 
Female. 
  
Group XRT (cGy) 
Treatment 5 days 
post-
BMT 
3 Month 
post-BMTb 
T cells Lin- cells 
Cohort A No No No 3M/3F 8M/8F 
Cohort B 900 2x 10
6  Mock-
Transduced T cells 
1.2-1.3 x 106  Mock-
Transduced Lin- cellsa 3M/3F 8M/8F 
Cohort C 900 2 x 10
6  Mock-
Transduced T cells 
1.2-1.3 x 106 TCR-
Transduced Lin- cellsa 3M/3F 8M/8F 
Cohort D 900 2 x 10
6 TCR-
Transduced T cells 
1.2-1.3 x 106  Mock-
Transduced Lin- cellsa 3M/3F 8M/8F 
Cohort E 900 2 x 10
6 TCR-
Transduced T cells 
1.2-1.3 x106 
TCR-Transduced Lin- 
cellsa 
3M/3F 8M/8F 
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Supplemental Table 6. Cell manufacturing acceptance criteria. 
 
Test  Item Experiment 1 Experiment 2 Experiment 3 Acceptability 
Criteria 
T cell puritya 93.0% 95.0% 90.0% >75% 
Lin- purity:  Lin- frequencyb Batch 1: 45.2%e 
Batch 2: 45.5%e 
Batch 3: 52%e 
Batch 1: 44.4% 
Batch 2: 48.6% 
Batch 3: 46.0% 
Batch 1: 44.1% 
Batch 2: 38.4% 
Batch 3: 52.7% 
>25% 
LSK frequencyc Batch 1: NA e 
Batch 2: NA e 
Batch 3: NA e 
Batch 1: 2.22% 
Batch 2: 2.47% 
Batch 3: 2.35% 
Batch 1: 3.13% 
Batch 2: 2.62% 
Batch 3: 2.9% 
No limit 
established 
LV VCN in Lin- cells (2 
weeks after culture) 
Mock: 0  
TCR: 1.44 
Mock: 0  
TCR: 1.81 
Mock: 0  
TCR: 1.61 
 
0.6-3 
RV VCN in T cells (2 weeks 
after culture) 
Mock: 0  
TCR: 3.67 
Mock: 0  
TCR: 5.28 
Mock: 0  
TCR: 4.9 
No limit 
established 
T cell viability (day of 
administration) 
Mock: 70.8% 
TCR: 66.7% 
Mock: 88.6% 
TCR: 86.9% 
Mock: 81.0% 
TCR: 77.6% 
> 65% 
Lin- cell viability (day of 
administration) 
Mock: 69.3% 
TCR: 65.3% 
Mock: 75.6% 
TCR: 69.2% 
Mock: 68.4% 
TCR: 65.9% 
> 65% 
Mycoplasma 
contamination 
T cells 
mock 
Negative Negative Negative Negative 
T cell 
transduced 
Negative Negative Negative Negative 
Lin- mock Negative Negative Negative Negative 
Lin- 
transduced 
Negative Negative Negative Negative 
Endotoxin 
concentration 
Cohort B: <5EU/Kg <5EU/Kg <5EU/Kg <5EU/Kg 
Cohort C: <5EU/Kg <5EU/Kg <5EU/Kg <5EU/Kg 
Cohort D: <5EU/Kg <5EU/Kg <5EU/Kg <5EU/Kg 
Cohort E: <5EU/Kg <5EU/Kg <5EU/Kg <5EU/Kg 
Sterilityd T cells 
mock 
Negative Negative Negative Negative 
T cell 
transduced 
Negative Negative Negative Negative 
Lin- mock Negative Negative Negative Negative 
Lin- 
transduced 
Negative Negative Negative Negative 
Cell mix 
homogeneity  
(VCN) 
Cohort B: RV: 0 
LV: 0.00013 
RV: 0 
LV:0.000285 
RV: 0 
LV:0.000448 
Not established 
Cohort C: RV: 0.000395  
LV: 1.73 
RV: 0 
LV: 2.9 
RV: 0  
LV: 1.95 
Cohort D: RV: 6.31 
LV: 0.0051 
RV: 5.87 
LV: 0 
RV: 7.27 
LV: 0 
Cohort E: RV: 6.29 
LV: 1.57 
RV: 5.64 
LV: 3.07 
RV: 6.97 
LV: 1.46 
Cell mix 
Viability 
before and 
after 
administration 
Cohort B: Before: 79.8% 
After: 77.3% 
Before: 81.4% 
After: 73.4% 
Before: 83% 
After: 82%  
Not established 
Cohort C: Before: 77.2% 
After: NAf 
Before: 77.1% 
After: 73.9% 
Before: 77.4% 
After: 74.8% 
Cohort D: Before: 78.8% 
After: 79.9% 
Before: 81.2% 
After: 76.6% 
Before: 82.4% 
After: 83% 
Cohort E: Before: 74.0% 
After: 75.1% 
Before: 75.3% 
After: 72.5% 
Before: 76.6% 
After: 79.4% 
Given the high number of animals included in the study, it was divided into 3 experiments. Animals 
in Experiments 1 and 2 were euthanized at 3 months after BMT, while those in Experiment 3 were 
euthanized at 5 days after BMT. 
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a Assessed by the frequency of CD3+ cells in the single cell population. Measured by flow 
cytometry. 
b Assessed by the frequency of Lin- cells in the single cell population. Measured by flow cytometry.  
c Assessed by the frequency of Lin-, ScaI + c-kit+ (LSK) cells in the single cell population. 
Measured by flow cytometry. 
d As determined by no bacterial and fungal growth in a 14 day culture.  
e Lin- purity assessment performed on the same day of the Lin- purification did not work. Lin- 
purity checking was repeated the following day, and the gating strategy was set based on the 
unstained samples. LSK staining is not reliable, due to extended culture. Deviation from the study 
protocol was filed. 
f All cells were used for injection, so there was no sample available to assess the viability. 
EU, endotoxin units; LV, lentivirus; RV, retrovirus; VCN, vector copy number. 
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Supplemental Table 7. List of protocol-specific organs. 
 
Tissues for Evaluation Weight (g) Histopathology 
Spleen 
(collect sterilely) 
X, Whole spleen X 
Half for Histopathology. Half for VCN and 
flow 
Femur &Tibia (right limb) 
(collect sterilely) 
NA NA, used for VCN and flow 
Sternum  NA X, Decalcified 
Thymus & associated Fat 
Pad 
NA X 
Lungs  NA X 
Larynx, Thyroid Glands 
and Trachea 
NA X 
Heart X X 
Liver with Gall- Bladder  X X + Gall bladder 
Pancreas NA X 
Stomach NA X 
Duodenum NA X 
Ileum NA X 
Jejunum NA X 
Cecum NA X 
Colon NA X 
Mesenteric Lymph Nodes NA X 
Adrenal Glands NA X 
Kidneys X, Weigh together X, Right cross section, Left longitudinal 
section 
Urinary Bladder X X 
Ovary-Females 
 
X X 
Uterus NA X 
Testis with Epididymis-
Male 
X X 
Seminal Vesicle, Prostate 
Gland, Coagulating Gland-
Males 
 
NA X 
Eye with Optic Nerve NA X 
Brain (without olfactory 
bulbs) 
X X 
Skin & 
Mammary Glands-
Females 
NA X 
Quadriceps Femoris (left) NA X 
Femur &Tibia (left) NA X, Decalcified 
Remainder of 
Carcass/Tissues 
NA NA 
Gross Lessions 
(if observed) 
NA X 
20 
 
Supplemental Table 8. Manufacturing validation runs. 
*HD1, HD2 and HD3 were manufactured with GMP-comparable grade vector. 
#TNC recovery was calculated by dividing the number of the total nucleated cells (TNC) cells 
seeded for stimulation (Day 0) by the number of TNC harvested on Day 2 and multiplying by 
100%.  
&Analyses performed after cells are cultured for 14 days to avoid over estimating vector copy 
number (VCN) and potency due to the presence of un-integrated forms of the lentiviral vector.  
** Vβ13.1-NYESO TCR variant of the TCR β chain 
CFU, colony-forming units  
  
Test  Acceptance Criteria HD1* HD2* HD3* HD4 HD5 
CliniMACS enrichment 
CD34+ cell recovery 
after CliniMACS® 
enrichment 
≥40% 50%  50% 60% 74% 68% 
CD34+ cell purity 
after CliniMACS® 
enrichment 
≥50% 97.08% 87.94% 98.87% 98.10% 99.58% 
In Process tests  
Sterility (Day 0) Negative   Negative Negative Negative Negative Negative 
Sterility (Day 1) Negative   Negative Negative Negative Negative Negative 
TNC viability  ≥70% 98.8% 99.1% 99.0 94.7 99.5 
Cell Product (CP)  
TNC recovery# ≥80% 131% 94% 125% 59% 106% 
% CD34+ cell purity ≥50% 98.66% 93.14% 97.68% 94.14% 96.27% 
Vector copy 
number& 
0.1-2 copies/cell 0.1 0.1  0.3 0.4 0.4 
Sterility Bacterial
culture 
Negative Negative Negative Negative Negative Negative 
Fungal 
culture 
Negative  Negative Negative Negative Negative Negative 
Endotoxin 
concentration 
≤ 5 EU/Kg (HD weight) 0.095  
 
0.132  
 
0.139  
 
0.129 0.101 
Mycoplasma 
contamination 
Ratio<1 0.18  0.4 0.46  0.23  0.07 
CFU assay Report results  51±14% 64±4% 52±10% 36±1% 46±10% 
% LV-NYESO+ 
CFUs 
Report results  35.4% 22.4% 28.7% 43% 37% 
Vβ13.1** expression Report results 18.8% 13.2% 24.8% 30.9% 31.4% 
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Supplemental Table 9. Comparison between fresh and cryopreserved product at 1, 30, 90 
and 180# days. 
 
#The numerical results in the table are mean ± SD. Linear mixed modeling approach was adopted 
for statistical analysis to evaluate the long-term stability of the cryopreserved cell products. 
*FCP, fresh cell product; TCP, thawed cell product.  
** This time point was assessed only for cell products manufactured with GMP-grade vector  
Test Method Specifications 
FCP* 
(n=4) 
Days post-cryopreservation 
P 
value 
TCP* 
1d (n=2)** 
TCP 
30d (n=5) 
TCP 
90d (n=3) 
TCP 
180d (n=2) 
%CD34 cells 
(purity) 
Flow Cytometry 
(ISHAGE)  
≥50% 95.9±2.7 95.9±0.5 95.6±3.4 96.5±0.5 97.5±0.5 0.95 
%TNC viability  Trypan Blue manual 
count 
≥70% 
96.0±4.9 93.6±3.4 95.4±5.4 97.1±1.5 97.7±0.4 
0.17 
%CD34+ cell 
recovery 
Flow Cytometry 
(ISHAGE) 
Record results 
83.2±14.4 90.5±9.6 89.5±5.4 97.7±20.3 83.2±14.4 
0.31 
Endotoxin 
concentration  
Endosafe®PTS ≤ 5 EU/Kg  
0.12±0.02 0.14±0.06 0.12±0.04 0.10±0.04 0.10±0.06 
0.88 
Mycoplasma 
contamination 
MycoAlert test Ratio<0.9 
0.32±0.13 0.14±0.10 0.33±0.12 0.37±0.23 0.28±0.08 
0.53 
Sterility Bacterial culture No growth No growth No growth No growth No growth No growth N/A 
Fungal culture No growth No growth No growth No growth No growth No growth N/A 
%Vβ13.1 positive 
cells 
Flow Cytometry Record results 
22.0±7.7 32.0±0.8 26.6±1.2 19.5±1.2 9.5±0.5 
0.15 
CFU potential Methylcellulose 
culture 
(%CFU/cells plated) 
Record results 
51±11 40±9 45±9 48±8 49±4 
0.45 
%LV-NYESO 
TCR/sr39TK-
positive CFU 
ddPCR Record results 
29.2±5.9 40.0±4.2 31.7±9.2 20.5±5.7 25.9±0.1 
0.15 
Vector copy 
number (VCN) 
ddPCR  Record results 
0.2±0.2 0.4±0.0 0.3±0.1 0.2±0.1 0.2±0.1 
0.8 
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SUPPLEMENTAL MATERIALS AND METHODS 
Primary cells, viral vectors and mice 
Human peripheral blood mononuclear cells (PBMCs) were obtained from leukapheresis products 
from healthy donors. The leukapheresis products were collected under UCLA Institutional Review 
Board (IRB) approval # 10-001598. The human CD34+ cells were purchased from AllCells 
(Alameda, CA) or HemaCare (Van Nuys, CA). Murine splenocytes and bone marrow cells were 
collected fresh from HLA-A2/Kb transgenic mouse donors (1). For the in vitro immortalization 
assay, bone marrow cells from C57BL/6J mice were used. HLA-A2/Kb transgenic mice (1) and 
C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) were bred and housed under defined-
flora, specific pathogen-free conditions at the AAALAC-approved animal facility of the Division of 
Experimental Radiation Oncology, UCLA, and used under the UCLA Animal Research Committee 
protocol #2013-095 that was approved in advance by the Institutional Animal Care and Use 
Committee.  
The third-generation lentiviral vector encoding the codon-optimized α and β chains of the NY-
ESO-1 TCR (derived from the 1G4 TCR clone(2)) together with the suicide gene sr39TK (RRL-
MSCV-optNYESO-optsr39TK-WPRE) was generated by transient transfection in normal human 
kidney-derived HEK293T cells using the packaging plasmids (pMDL, pMDG1, and pRSV-Rev) 
and the vector plasmid (pRRL-MSCV-optNYESO-optsr39TK-WPRE). This vector was 
manufactured at the Indiana University Vector Production Facility (IUVPF, Indianapolis, IN) at 
GMP-comparable (cGMP) and GMP-compliant grades. Briefly, supernatant from the transfected 
cells was harvested, filtered, benzonase-treated to remove residual plasmid DNA, purified by 
Mustang Q ion exchange, concentrated by tangential flow filtration and formulated in X-VIVO 15 
serum-free medium. For the GMP-grade vector, all assays required by the FDA to ensure the 
absence of adventitious agents and replication-competent lentiviruses were performed 
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(Supplemental Tables 1-2). The control lentiviral vectors encoding the codon-optimized α and β 
chains of the NY-ESO-1 TCR alone (RRL-MSCV-optNYESO-WPRE) and the empty lentivirus 
control (RRL-MSCV-empty-WPRE) were provided by D.B.K. and R.P.H. These vectors were 
manufactured at research grade by transient transfection in HEK293T cells using the packaging 
plasmids pCMV-dR8.91 and pMDG-VSVG plasmids and the vector plasmids (pRRL-MSCV-
optNYESO-WPRE and pRRL-MSCV-empty-WPRE) as previously described (3). The ecotropic 
retroviral vector MSGV1-A2ab-1G4A-Ly3H10 was manufactured at IUVPF at cGMP grade by 
transient transfection in HEK293T cells of the vector plasmid pMSGV1-A2ab-1G4A-Ly3H10 (a 
kind gift from Dr. Paul F. Robbins and Dr. Steven A. Rosenberg) and the pCL-Eco plasmid (kind 
gift from Dr. Inder Verma (Addgene plasmid # 12371)(4) encoding for retroviral Gag, Pol and the 
ecotropic envelope proteins. The ecotropic SF91-eGFP-RRE retroviral vector was manufactured 
at IUVPF using a polyclonal GP+E producer cell line generated by D.B.K and R.P.H. 
 
Peripheral blood mononuclear cell (PBMC) activation, transduction and expansion 
Healthy donor PBMCs were thawed and activated for two days in RPMI (Corning, Corning, NY) 
media with 10% fetal bovine serum (FBS, Omega Scientific, Tarzana, CA), 50ng/ml OKT-3 
(Miltenyi Biotec, Bergisch Gladbach, Germany) and 300 IU/mL rhIL-2 (Proleukin; Prometheus 
Laboratories, San Diego, CA). Two days after activation, PBMCs were either mock-transduced 
or transduced with the LV-NY-ESO-1 TCR/sr39TK at a multiplicity of infection (MOI) of 100 ifu/cell 
in retronectin-coated plates (Takara Bio USA, Inc, Mountain View, CA). PBMCs were expanded 
for 3 days. After expansion, the expression of the NY-ESO-1 TCR at the cell surface was 
measured by NY-ESO-1(157-162) (SLLMWITQV)-PE and matching HLA-negative dextramer 
(Immudex, Copenhagen, Denmark) in conjunction with a CD3-Brilliant Violet (BV)-650, CD4-
BV510, CD8-BV605 (Biolegend, San Diego, CA), as well as 7-Aminoactinomycin D (7AAD) 
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(Beckman Coulter, Brea, CA) staining. Acquisition was done using two LSR II Flow Cytometers, 
both with four lasers (blue, red, violet, and ultraviolet; BD Biosciences, San Jose, CA). All flow 
cytometry data analyses were done with FlowJo v9 or v10 (Tree Star Inc., Asland, OR). 
Biexponential displays were used in the analyses. 
 
CD34+ cell enrichment, stimulation, transduction, final formulation and cryopreservation. 
The CD34+ cell population was enriched using the CliniMACS®CD34 reagent system (Miltenyi 
Biotec, Bergisch Gladbach, Germany) following the manufacturer’s instructions.  The enriched 
CD34+ cell population was pre-stimulated overnight at a concentration of 1x106 cells/mL in X-
VIVO15 medium (Lonza, Walkersville, MD) supplemented with the following cocktail of GMP-
grade recombinant human (rh) cytokines: rhSCF (50ng/mL), Flt-3 ligand (50ng/mL), TPO (50 
ng/mL) and IL-3 (20ng/mL) (all from Miltenyi Biotec). After 18±6 hours of pre-stimulation, 
transduction of the peripheral CD34+ cells was performed in retronectin-coated plates using 
GMP-comparable or clinical-grade LV-NYESO TCR/sr39TK vector supernatant at a final MOI of 
50 (two transduction cycles of 25 MOI each). After 18±6 hours from the first transduction, cells 
were harvested and formulated in cryopreservation solution consisting of Plasmalyte-A (Baxter 
Healthcare, Deerfield, IL); 5% DMSO (Cryoserv, Mylan Inc., Canonsburg, PA); 6% Pentastarch 
(Preservation Solutions Inc., Elkhorn, WI) and 5% human serum albumin (HSA; Grifols, Los 
Angeles, CA). The final cell product was cryopreserved using a controlled-rate freezer.  
 
Suicide gene sr39TK activity 
Human CD34+ cells mock-transduced and transduced with the lentivirus LV-NY-ESO-1 
TCR/sr39TK were cultured for 72 hours. After expansion, the cells were harvested and seeded in 
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fresh basal media at 1x106 cells/mL in 24 well-plates coated with retronectin (20µg/mL).  Cells 
were then treated with ganciclovir (Gemini Bio-Products, Sacramento, CA) at concentrations of 
0, 0.02, 0.2, 2, 20 or 200 µM for 48 hours. The percentage of cells co-expressing NY-ESO-1 TCR 
and sr39TK was assessed by flow cytometry analysis. Briefly, Zombie Violet Fixable Viability Kit 
(Biolegend, San Diego, CA) for exclusion of dead cells was used, following the manufacturer’s 
instructions. Then, the cells were permeabilized using BD Cytofix/Cytoperm™ kit (BD Bioscience, 
San Jose, CA) and intracellular staining of the NY-ESO-1 TCR beta chain (anti-human TCR 
Vβ13-PE, clone IMMU222 Beckman Coulter) was performed.  FBS (Omega Scientific) was used 
to block. Vβ13 isotype controls (IgG2b, κ isotype-PE, clone 27-35, BD Bioscience) were used to 
set the gates. Acquisition was performed as described above.  
 
Lin- cell purification, transduction and expansion 
The Lin- population was isolated from the total bone marrow using the Mouse Hematopoietic 
Progenitor Cell Enrichment (StemCell Technologies, Vancouver, Canada) negative selection kit. 
Briefly, HLA-A2/Kb transgenic mice (for the bone marrow transplantation (BMT) studies) or 
C57BL6/J mice (for the in vitro immortalization experiment) were euthanized, the femurs and 
tibias were collected and cleaned, and the bone marrow was recovered by flushing the marrow 
cavities with Robosep buffer (StemCell Technologies). Cells from multiple donors were pooled 
and resuspended at a concentration of 1x108 cells/mL in Robosep buffer. The purification was 
performed in batches if more than 5x108 cells needed to be processed. 50µL/mL of normal rat 
serum and 50µL/mL of EasySep Mouse Hematopoietic Progenitor Cell Isolation Cocktail 
(StemCell Technologies) were added to the cells and incubated for 30 min on ice. The cells were 
washed, and 100 μL/mL of EasySep Biotin Selection Cocktail (StemCell Technologies) was 
added for a 30-min incubation on ice. After incubation, 75 μL/mL of magnetic particles (StemCell 
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Technologies) were added and incubated for 10 min on ice. The EasySep Magnet (StemCell 
Technologies) was used to retain all of the lineage-positive cells. The fraction of cells not retained 
by the magnet was considered to be the Lin- cell fraction. To assess the purity, total bone marrow 
cells and the Lin- cell fraction were stained with antibodies for the lineage markers CD3e-FITC 
(Clone 145-2C11, eBioscience, San Diego, CA), CD45R-FITC (Clone RA3-6B2, eBioscience), 
CD19-FITC (Clone 6D5, StemCell Technologies), CD11b-FITC (Clone M1/70, eBioscience), Gr1-
FITC (Clone RB6-8C5, eBioscience) and TER119-FITC (Clone TER-119, eBioscience) and the 
progenitor stem cell markers ScaI-PE-Cy7 (Clone D7, eBioscience) and cKIT-APC (Clone: 2B8, 
eBioscience). Purified CD16/32 (clone 93, eBioscience) was used to block. The percentage of 
Lin- cells and the frequency of ScaI+ and cKIT+ cells in the Lin- population were measured by 
flow cytometry.  
After purification, cells were seeded at 0.5x106 cells/mL in StemSpan SFEM media (Stem Cell 
Technologies) supplemented with L-glutamine, penicillin and streptomycin (Gemini BioProducts, 
West Sacramento, CA), 50ng/mL of mSCF (R&D Systems, Minneapolis, MN), 100ng/mL hIL-11 
(R&D Systems), 20ng/mL mIL-3 (R&D Systems) and 100ng/mL of hFlt3-L (R&D Systems). The 
Lin- cells were pre-stimulated between 18-20 hours and 2 days. After pre-stimulation, the cells 
were transduced with the indicated lentiviral vectors using an MOI of 2-7.5 (an MOI of 7.5 ifu/cell 
was used for the GLP co-administration studies) and seeded in retronectin-coated plates. The 
cells were transduced and cultured for an additional 24-48 hours. Shorter pre-stimulation times 
(18-20 hours) and expansion times (24 hours) improved stem cell engraftment and long-term 
survival of the mice receiving BMT. Mock-transduced Lin- cells were manufactured in parallel to 
be used for the control groups. 
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T cell purification, transduction and expansion 
The T cells were purified from spleens of HLA-A2/Kb transgenic mice. Briefly, the mice were 
euthanized, the spleens were collected in sterile conditions and a single cell splenocyte 
suspension was obtained by dissociating the spleens with a syringe plunger through a 70 μm 
porous mesh nylon strainer and then washing them with Robosep buffer (StemCell Technologies). 
The T cells were purified from the single cell suspension by negative selection using the 
EasySep™ Mouse T cell Isolation Kit (Stem Cell Technologies) according to the manufacturer’s 
instructions. To assess the purity, splenocytes and purified T cells were stained with an anti-
CD3e-FITC (Clone: 145-2C11; eBioscience) antibody. Purified CD16/32 antibody (clone 93; 
eBioscience) was used to block, and 7-amino-actinomycin-D (7-AAD, Beckman Coulter) was 
used as a viability marker. The analysis was performed by flow cytometry as descried above. 
After purification, the T cells were activated with CD3/28 beads (Invitrogen, Carlsbad, CA) using 
a 1:1 ratio and expanded for one day in RPMI media supplemented with 10% FBS, 0.05mM 2-
mercaptoethanol (Invitrogen), penicillin-streptomycin (Invitrogen), 20mM HEPES (Corning), 1mM 
sodium pyruvate (Invitrogen) and 40 IU/mL of mIL-2 (Peprotech, Rocky Hill, NJ). The next day, T 
cells were collected and transduced with the RV-NY-ESO-1 TCR by spinoculation in retronectin-
coated plates using a 1:1 mix of vector supernatant and fresh media. After transduction, cells 
were expanded for 3 more days. Mock-transduced T cells were manufactured in parallel to be 
used for the control groups. 
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Bone marrow transplantation in myelodepleted HLA-A2/Kb host mice 
After Lin- and T cell purification, transduction and expansion, cells were collected, washed in PBS 
and resuspended in PBS at the final concentration needed for administration to the mice. The 
CD3/CD28 beads were removed from the T cell preps. As part of the acceptance criteria in the 
GLP studies, several parameters were measured: i) viability in each cell suspension was 
measured using AO/PI (acridine orange (AO) and propidium iodide (PI); Nexcelom, Lawrence, 
MA) and an automatic cell counter (Nexcelom Cellometer Auto 2000, Nexcelom); ii) samples of 
the cell supernatant were used for mycoplasma contamination testing using MycoAlert 
Mycoplasma Detection Kit (Lonza); iii) cell supernatant samples were sent to Labs, Inc. 
(Centennial, CO) for sterility testing; iv) a fraction of each cell type was kept in culture for two 
weeks for VCN determination; and v) a fraction of each cell preparation was cryopreserved in 
liquid nitrogen and archived as part of the reserved samples for the GLP studies.  
For the co-administration GLP studies, each of the cell suspensions was prepared at twice the 
desired final concentration of cells after which Lin- and T cell preparations were mixed 1:1 in 
volume to generate the final cell preparations ready for administration to the mice. The final 
volume administered was 200µL per mouse, containing two million T cells and between 0.2 and 
2 million Lin- cells. As part of the acceptance criteria for the GLP studies, several parameters 
were also measured in the cell mixtures: i) cell pellets were collected to measure the endotoxin 
concentration in the final product using the Endosafe-PTS system (Charles River Laboratories, 
Wilmington, MA); ii) cell pellets were used to measure the lentivirus and retrovirus VCN; and iii) 
the cell viability in the cell mixtures was measured with AOPI and an automatic cell counter before 
and after cell administration to the mice.  
The single cell preparations or the mixtures of Lin- and T cells were administered intravenously 
in the lateral tail vein to HLA-A2/Kb mice that had previously received lethal total body irradiation 
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of 900cGy (J.L. Shepherd Mark I Irradiator, San Fernando, CA). To help improve mouse recovery 
after irradiation, water supplemented with 0.25 mg/mL amoxicillin (Biomox, Virbac AH, Inc., Fort 
Worth, TX) and DietGel 76A (ClearH2O, Westbrook, ME) was provided ad libitum. Clinical 
observations and body weight measurements were performed and documented at least twice a 
week for the duration of each experiment.  
Necropsies and sample processing 
After bone marrow transplantation, mice were followed for three months unless otherwise 
indicated. Five days or three months after BMT, mice were euthanized by CO2 asphyxiation. 
Cardiac blood was collected and used for hematology, serum chemistry (only for the mice 
euthanized at three months after BMT) and VCN determination as determined by the study 
protocols. Blood samples for hematology and serum chemistry were processed by Quality Vet Lab 
(Davis, CA) for the GLP-compliant studies and the UCLA Division of Laboratory Animal Medicine 
(Los Angeles, CA) or IDEXX BioResearch, (West Sacramento, CA) for the non-GLP research 
studies. Blood smears were performed as a backup. The spleen and bone marrow were collected 
and single bone marrow cells and splenocyte single cell suspensions were prepared for VCN 
determination and cell phenotype characterization (only for the mice euthanized at three months 
after BMT). If full pathology analysis was needed, the protocol-specified organs indicated in 
Supplemental Table 7 were collected and weighed (for selected organs). Tissues for histopathologic 
assessment were sent in GTF™ Formalin Substitute (Stat Lab McKinney, TX) to HistoTox Labs 
(Boulder, CO) to be processed in a GLP-compliant manner. Sections stained with H&E were 
analyzed by an ACVP board-certified veterinary pathologist (B.B).  
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Vector Copy Number 
At least 0.5x106 Lin- and T cells (each cultured for 2 weeks), 1-3x106 bone marrow cells and 
splenocytes and 100 μL of blood samples were used to extract DNA using the DNeasy Blood & 
Tissue Kit (Qiagen, Germantown, MD). Vector copy number (VCN) was determined for all DNAs 
via digital droplet PCR (ddPCR; BioRad, Hercules, CA) using the primer/probe sets (Integrated 
DNA Technology, Coralville, IA) specific for the lentiviral (assessed in 2-week cultured Lin- cells, 
blood, bone marrow cells and splenocytes) and retroviral vectors (assessed in 2-week cultured T 
cells, blood, bone marrow cells and splenocytes).  A primer/probe set for the mouse specific uc378 
region was used as internal calibrator. The primers and probes are the following: for the retroviral 
vector, Retro NYESO1 F (CCGGGTTTAATCTGCTCATG), Retro NYESO1 R 
(AGGCTGCACAGCACAGGAGG), Retro NYESO probe (/56-FAM/TGAAGTTGG 
/ZEN/TGGCTCCGGATCC/3IABkFQ/); for the lentiviral vector, HIVU5 F 
(AAGTAGTGTGTGCCCGTCTG), HIVpsi R (CCTCTGGTTTCCCTTTCGCT), HIV1U5 probe (/6-
FAM/CCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAG/Iowa);  for the internal calibrator, 
uc378 F (CGCCCCCTCCTCACCATTAT), uc378 R (CATCACAACCATCGCTGCCT), uc378 HEX 
probe (5' HEX-TTACCTTGCTTGTCGGACCAAGGCA-3' Iowa Black). For human bulk CD34+ cell 
cultures and single CFUs,  the cellular autosomal gene syndecan 4 (SDC4) was used as the 
internal calibrator using the following probes: SDC4 F (CAGGGTCTGGGAGCCAAGT), SDC4 R 
(GCACAGTGCTGGACATTGACA), SDC4 HEX (5' HEX- 
CCCACCGAACCCAAGAAACTAGAGGAGAAT- 3' Iowa Black). For the IVIM studies, a primer 
probe set amplifying the GFP transgene was used to measure the VCN of the cells transduced 
with SF91-eGFP-WPRE. The sequences or the primer probe set are eGFP616F 
(CTGCTGCCCGACAACCA), eGFP705R (GAACTCCAGCAGGACCATGTG) and eGFP653 
FAM Probe (6FAM—CCCTGAGCAAAGACCCCAACGAGA—Iowa Black FQ).  
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Flow cytometry 
The expression of the NY-ESO-1 TCR and the bone marrow and splenocyte phenotype 
characterization were assessed by flow cytometry three months after BMT. Briefly, surface 
staining for multiple T cell markers [anti-mouse CD3e-FITC (clone 145-2C11), anti-mouse CD4-
APC (clone RM4-5; BD Bioscience), anti-mouse CD8a-APC-Cy7 (clone 53-6.7; BD Bioscience), 
anti-mouse NK1.1-BV421 (clone PK136; Biolegend)], B cells and granulocyte markers [anti-
mouse IgM- PECy7 (clone 11/41; eBioscience), anti-mouse Ly-6G-APC (clone 12B-8C5; 
eBioscience), anti-mouse CD11b-APC-eFluor780 (clone M1/70; eBioscience), anti-
human/mouse B220-FITC (clone RA3-6B2; eBioscience) and anti-mouse F4/80-BV421 (clone 
BM8; eBioscience)] and the NY-ESO-1 TCR beta chain (Vβ13, anti-human TCR Vβ13-PE, clone 
IMMU222; Beckman Coulter) was performed in splenocyte samples followed by cell 
permeabilization using BD Cytofix/Cytoperm™ kit (BD Bioscience) according to the 
manufacturer’s instructions and intracellular staining of the NY-ESO-1 TCR beta chain (Vβ13). 
Surface staining for lineage and stem cell progenitor markers [anti-mouse CD3e-FITC (clone 145-
2C1; eBioscience), anti-mouse CD8a-FITC (clone 53-6.7; eBioscience), anti-mouse NK1.1-FITC 
(clone PK136; eBioscience), anti-mouse TCRb-FITC (clone H57-597; eBioscience), Anti-mouse 
γ/δTCR-FITC (clone UC7-13D5; eBioscience), anti-human/mouse B220-FITC (clone RA3-6B2; 
eBioscience), anti-mouse Ly-6G (Gr-1)-FITC (clone RB6-8C5; eBioscience), anti-mouse TER-
119-FITC (clone TER-119; eBioscience), anti-mouse CD11b-FITC (Clone M1/70; eBioscience), 
anti-mouse IgM-FITC (Southern Biotech, Birmingham, AL), anti-mouse CD117 (c-Kit)-APC (clone 
2B8; eBiosicence), anti-mouse Ly-6A/E  (Sca-1)-PECy7 (clone D7; eBioscience), anti-mouse 
CD150-BV421 (clone TC15-12F12.2, Biolegend) and anti-mouse CD48-APC-eFluor780 (clone 
HM 48-1, eBioscience) and the NY-ESO-1 TCR beta chain (Vβ13) was performed in bone marrow 
samples followed by cell permeabilization using BD Cytofix/Cytoperm™ kit and intracellular 
staining of the NY-ESO-1 TCR beta chain (Vβ13).  Purified anti-mouse CD16/32 (clone 93; 
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eBioscience) was used to block. Vβ13 isotype controls (IgG2b, κ isotype-PE, clone 27-35; BD 
Bioscience) and fluorescence minus one (FMOs) controls were used.  
Surface and total expression of the NY-ESO-1 TCR was measured in murine T cells transduced 
with the retroviral vector. Surface staining was performed using the Vβ13 antibody according to 
manufacturer’s instructions. For the total NY-ESO-1 TCR expression, after surface staining with 
the Vβ13 antibody, cells were permeabilized using BD Cytofix/Cytoperm™ kit and stained for 
intracellular Vβ13 using the same antibody. Purified anti-mouse CD16/32 (clone 93; eBioscience) 
was used to block and isotype IgG2b was used as a control. Acquisition and analysis was 
performed as described above. 
 
In vitro immortalization assay 
Lin- cells from C57BL/6J mice were transduced with LV-NY-ESO-1 TCR/ sr39TK or the SF91-
eGFP-WPRE retrovirus control in retronectin-coated plates using MOIs of 25, 50, 335, 670, 1005 
and 1675 for the lentivirus and 1, 5, 10 and 20 for the retrovirus. After transduction, cells were 
cultured for 2 weeks. The VCN was determined by droplet digital PCR (ddPCR) eight days after 
transduction. After mass expansion for 2 weeks, cells were plated in limiting dilution in 96 well 
plates at 100 cells/well and 1000 cells/well and cultured for an additional 2 weeks. The number of 
wells containing immortalized clones was counted and the replating frequency was calculated 
using ELDA extreme limiting dilution software (5) (http://bioinf.wehi.edu.au/software/elda) for 
each sample. The replating frequencies were normalized by the VCN.  
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CD34+ cell quality assessment tests 
At least 10% of the CD34+ final cell product was reserved to test for sterility, endotoxin levels, 
mycoplasma contamination, clonogenic potential and transduction efficiency. Sterility was 
assessed by bacterial and fungal cultures for 14 and 21 days, respectively, at the Clinical 
Microbiology Labs (UCLA). Endotoxin levels were assessed by using the Endosafe®-PTSTM test 
system. Mycoplasma was assessed by the MycoAlert™ Mycoplasma Detection Kit. The number, 
purity and viability of CD34+ cells before/after enrichment and in the cell product were evaluated 
using the single-platform ISHAGE flow cytometric method (6).  Intracellular Vβ13 chain expression 
(TCR β chain variant specific for NY-ESO-1 TCR) was assessed by flow cytometry. 
Colony-forming unit (CFU)  potential was evaluated by culturing CD34+ cells in a methylcellulose-
based medium MethoCultTM H4435 Enriched (StemCell Technologies). 1x102 and 1x103 viable 
cells were plated in duplicate in 35mm culture dishes and incubated for 13-15 days in a humidified 
5% CO2 incubator. Colonies were counted using an inverted phase contrast microscope and 
characterized based on their unique morphology (7). 
The VCN of integrated lentivirus per cell of the bulk cell culture was assessed by plating 5×104 
cells in Iscove's Modified Dulbecco's Medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, 
MA) supplemented with 20% (vol/vol) FBS (Omega Scientific), 1% (vol/vol) L-glutamine, and 
penicillin-streptomycin mixture (Gibco; Thermo Fisher Scientific, Inc) as well as rhIL-3 (5ng/ml), 
rhIL-6 (10 ng/ml) and rhSCF (25 ng/ml) (Miltenyi Biotec, Bergisch Gladbach, Germany). The cells 
were cultured for 14 days. The average VCN per cell was determined by ddPCR, as described 
above.  
Single CFUs were individually picked to identify the percentage of  LV-NYESO TCR/sr39TK-
positive  CFUs. The genomic DNA was isolated using NucleoSpin® Tissue XS kit (Macherey-
Nagel, Bethlehem, PA). The number of positive colonies was assessed by ddPCR. 
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LV-NYESO TCR/sr39TK PBSC stability evaluation 
The long-term stability of the frozen cell product was evaluated after storage in the vapor phase 
of liquid nitrogen (≤-140°C) for 30±7, 90±7 and 180±10 days. To evaluate the post-thaw stability 
over a 48-hour period (short-term), the thawed cell product was split into two cryo-bags.  One bag 
was stored at ambient room temperature and the other was refrigerated at 4-8°C in a temperature-
monitored refrigerator. At each of the 3, 6, 24 and 48-hour time points, 1-1.5 mL samples were 
taken from each of the bags and evaluated for TNC numbers, viability, CD34+ cell numbers and 
CFU potential. 
 
Differentiation of NYESO TCR/sr39TK-engineered T cells in ATOs (artificial thymic 
organoids) 
Performed as described in (8). 
 
Statistical analysis  
Overall survival estimates of animals receiving BMT were obtained by Kaplan-Meier product-limit 
method and plotted by treatment cohorts.  Comparison of overall survival between treatment 
cohorts was performed via the log-rank test. For quantitative outcomes including lentivirus/ 
retrovirus VCNs, splenocyte and bone marrow cell counts, frequencies of bone marrow cell 
subsets, frequencies of splenocyte cell subsets, body and organ weights, hematological and 
serum chemistry parameters, descriptive statistics (such as number of animals, mean, standard 
deviation, minimum and maximum by treatment groups) were calculated. Pair-wise comparisons 
of least-squares means in a linear model framework with Tukey-Kramer adjustment for multiple 
testing was used to measure the statistical significance. For the VCN analysis in the 
immunogenicity study (Figure 5), normality assumption was not met for the data and consequently 
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the pair-wise comparison analysis was performed using the non-parametric Dwass, Steel, 
Critchlow-Fligner method to adjust for multiple comparisons.   
To assess the differences in the replating frequency/VCN between the SF91-eGFP-WPRE 
positive control and the LV-NY-ESO-1 TCR/ sr39TK, two different statistical tests were applied, 
Fisher’s exact test for comparing the dichotomized positive/negative replating frequency/VCN and 
Wilcoxon rank sum test for the quantitative replating frequency/VCN. 
A linear mixed modeling approach was adopted to evaluate the long-term stability and short-term 
stability of the cryopreserved cell products. Specifically, donor-to-donor variations were modeled 
through random intercepts, while time was treated as a fixed effect. Within the linear mixed model 
framework, an overall test of time effect was performed, followed by Tukey-Kramer adjusted 
pairwise comparisons.  
For all statistical investigations, tests for significance were two-tailed. A p-value less than the 0.05 
significance level was considered to be statistically significant. All statistical analyses were carried 
out using SAS software (version 9.4; SAS Institute Inc. 2013). 
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1.0 KEY PERSONNEL 
 
Study Director Cristina Puig Saus, PhD 
Postdoctoral Fellow 
Telephone No.: 310-500-5735 
E-mail: cpuigsaus@mednet.ucla.edu 
Test Facility Liaison  
(Ribas Laboratory) 
 
 
 
Test Facility Liaison   
(DLAM) 
 
 
Project Scientist 
Paula Kaplan-Lefko, PhD 
Project Manager 
Telephone No.: 310-206-2090 
E-mail: PKaplanLefko@mednet.ucla.edu 
 
Jeffrey Goodwin, DVM, PhD, DACLAM 
DLAM Executive Director 
Telephone No.: 310-794-0286 
E-mail: JGoodwin@mednet.ucla.edu 
 
Giulia Parisi, PhD 
Postdoctoral Fellow 
Telephone No.: 424-744-9344 
E-mail: gparisi@mednet.ucla.edu 
Project Scientist James McCabe 
Animal Health Technician  
Telephone No.: 805-341-2898 
E-mail: jmccabe@mednet.ucla.edu 
Project Scientist Salemiz Sandoval, PhD 
Assistant Project Scientist 
Telephone No.:  626-780-8379 
 E-mail: salemizsandoval@mednet.ucla.edu 
Test Facility Veterinarian Joanne Zahorsky-Reeves, DVM, PhD, DACLAM 
Senior Clinical Veterinarian 
Telephone No.: 310-794-0255 
E-mail: jreeves@mednet.ucla.edu 
 
Test Facility Veterinarian 
(backup) 
Cristobal Torres, DVM, MPH 
Clinical Veterinarian 
Telephone No.: 310 694 7210 
E-mail: ctorresurbano@mednet.ucla.edu 
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Quality Assurance Unit Denise Breazeal 
Quality Assurance Unit 
Telephone No.: 310-825-2845 
E-mail: dbreazeal@mednet.ucla.edu 
Biostatistician Xiaoyan Wang, PhD 
Adjunct Assistant Professor 
Telephone No.:  310-794-3114 
E-mail:  xywang@mednet.ucla.edu 
 
2.0 TEST SITES 
 
Test Site for Sterility Test 
Company Labs Inc. 
6933-B S Revere Pkwy  
Centennial, CO 80112 
 
Primary Contact for Sterility 
Testing 
Monroe A. Burgess, CTBS 
Regional Manager - West 
Telephone No.: 520.990.1573/ 800.321.6088 
E-mail: Monroe_Burgess@labs-inc.org  
 
Test Site for Hematology and Serum Chemistry 
Company Quality Veterinary Laboratory 
2121 2nd Street, C-104  
Davis, CA 95618 
 
Principal Investigator for 
Hematology and Serum 
Chemisty 
Joan Shewmaker CLS, MT(ASCP) 
Manager  
Telephone No.: 530-759-8533 
Fax: 530-759-8553 
E-mail: joan@qualityvetlab.com 
 
Quality Assurance Contact Marvin Chaw 
QA Consultant 
Telephone No.: 530-759-8533 
E-mail: emcee3consulting@gmail.com 
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Test Sites for Histology and Anatomic Pathology 
Company (histology) HistoTox Labs, Inc. 
2108 55th St, Suite 110 
Boulder, CO 80301 
Primary Contact for Histology 
Processing 
Jon Bishop 
President 
HistoTox Labs, Inc. 
Telephone No.: 303-633-5401 
E-mail: jbishop@histotoxlabs.com 
Principal Investigator for 
Anatomic Pathology 
Brad Bolon, DVM, MS, PhD, DACVP, DABT, 
FATS, FIATP 
GEMpath, Inc. 
1100 East 17th Avenue, Unit M202 
Longmont, CO  80504 
Telephone No.: 720-209-1105 
E-mail: bradgempath@aol.com 
 
Quality Assurance Contact for 
Histology and Anatomic 
Pathology 
Kendy L. Keatley, BS 
HistoTox Labs, Inc. Contract QA 
2200 24th Ave. 
Longmont, CO  80501 
Telephone No.: 303-485-3876 
E-mail:  klkeat@msn.com 
 
3.0 PROPOSED STUDY TIMETABLE 
 
Experimental Start Date 
 
27th April 2016 
 
Cell Therapy Manufacturing Experiment 1: 9th May – 13th May 2016 
Experiment 2: 16th May – 20th May 2016 
Experiment 3: 20th June – 24th June 2016 
 
In-life  Start Date 
 
Experiment 1: 13th May 2016 
Experiment 2: 20th May 2016 
Experiment 3: 24th June 2016 
 
In-life End Date  Experiment 1: 8th -9th August 2016 
Experiment 2: 15th -16th August 2016 
Experiment 3: 29th June 2016 
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Experimental Termination Date November 2016 
 
Unaudited Draft Report Date November 2016 
 
Study Completion Date Date the Study Director signs the final 
report 
  
4.0 OBJECTIVES 
 
The goal of this study is to assess the safety of the co-administration of T cells transduced with 
retrovirus encoding NY-ESO-1 T cell receptor (TCR) and hematopoietic stem cells (HSCs) 
transduced with lentivirus encoding NY-ESO-1 TCR/sr39TK in HLA-A2.1/Kb mice.  Safety of 
co-administration will be compared to that observed in animals receiving control mock 
transduced HSCs and mock transduced T cells, mock transduced HSCs and transduced T cells, 
transduced HSCs and mock transduced T cells and animals receiving no treatment.  The 
parameters to be assessed include: 1) the effect of co-administration on engraftment of 
transduced T cells and HSCs and 2) the effect of co-administration on hematopoietic cell lineage 
development. 
 
5.0 JUSTIFICATION 
 
We and others have conducted adoptive cell therapy clinical trials using T cells transduced with 
a retroviral NY-ESO-1 TCR vector.  We plan to now test the use of NY-ESO-1 TCR transduced 
T cells in combination with hematopoietic stem cells (HSCs) transduced with a lentiviral NY-
ESO-1 TCR/sr39TK vector.  The purpose of this toxicity study is to assess: 
 The safety of the co-administration of this combination since it is possible that the 
transduced T cells and transduced HSCs could interfere with the engraftment of the other 
cell type or that co-administration of T cells and HSCs together could adversely affect 
hematopoietic cell lineage development.  
 
6.0 REGULATORY COMPLIANCE 
 
The experiments described in this proposal will be performed at an academic biomedical 
research center (University of California, Los Angeles (UCLA)) in accordance with the United 
States Food and Drug Administration (FDA): Good Laboratory Practice (GLP) for Nonclinical 
Laboratory Studies, Code of Federal Regulations, Title 21 Part 58.  Relevant standard operating 
procedures (SOPs)/protocols will be followed.   
 
Exceptions to GLPs include the following study elements. 
 The sterility test to be performed by LABS, Inc., a comprehensive, highly accredited and 
licensed clinical reference testing laboratory, will be performed according to all 
requirements for clinical samples. 
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 The irradiator located in the Biological Sciences Research Building used to irradiate mice 
will not be calibrated.  Standard operating procedures are used and biannual safety 
inspections are performed by EH&S (UCLA office of Environment, Health and Safety).  
A myelodepleting dose of radiation has been established for the mice used in this 
protocol in previous experiments, and myelodepetion will be assessed in the current 
protocol at day 5 after irradiation.   
 
7.0 ANIMAL CARE AND USE STATEMENT 
 
UCLA’s animal research facilities are fully accredited by the Association for the Assessment and 
Accreditation of Laboratory Animal Care (AAALAC).  All procedures in this study will comply 
with all applicable sections of the Final Rules of the Animal Welfare Act regulations (9 CFR:  
Parts 1, 2 and 3) and the Guide for the Care and Use of Laboratory Animals (National Research 
Council, National Academy Press, Washington, D.C., Copyright 2011). 
8.0 VETERINARY CARE/PALLIATIVE AND PROPHYLACTIC MEASURES 
 
In accordance with the Animal Welfare Act (U.S.C Title 7 Chapter 54 Transportation, Sale and 
Handling of certain animals and CFR Title 9 Chapter 1 Subchapter A Animal Welfare), the 
Guide for the Care and Use of Laboratory Animals (8th edition, National Research Council) and 
the Office of Laboratory Animal Welfare, medical treatment necessary to prevent unacceptable 
pain and suffering, including euthanasia, is the sole responsibility of the clinical veterinarian. 
Supportive care such as saline injections will be provided to mice if signs of dehydratation or 
other toxicity associated with irradiation appear. Palliative and prophylactic procedures may be 
based upon consensus agreement between the study director and clinical veterinarian.  The study 
director and sponsor/designee (if possible) will be included in discussions of palliative and 
prophylactic procedures recommended by the clinical veterinarian. The clinical veterinarian, the 
study director and the sponsor (if possible) will make all decisions concerning the health and 
wellbeing of the animals and any subsequent decision to euthanize them.  
9.0 TEST AND CONTROL ARTICLES 
 
The test articles for this study are HSC enriched lineage depleted bone marrow cells (Lin-) and 
splenic T cells obtained from HLA-A2.1/Kb mice that are transduced under one of the following 
conditions:   
 
1) Lin- bone marrow cells transduced ex vivo with LV-NY-ESO-1 TCR/sr39TK lentiviral vector 
(test article 1)  
2) T cells transduced ex vivo with RV-NY-ESO-1 TCR retroviral vector (EcoMSGV1-A2aB-
1G4A-Ly3H10) (test article 2)  
3) Lin- bone marrow cells and T cells cultured in their respective medium without lentiviral or 
retroviral vector (control articles). 
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Test articles and control articles will be combined according to Tables 1-2 to generate the 
different treatments.  
 
Both vectors were produced at Good Manufacturing Practice (GMP)-Comparable grade at the 
Indiana University Vector Production Facility (IUVPF, Indianapolis, IN).  The IUVPF will 
provide documentation on the lot number, sterility, endotoxin and mycoplasma assessment for 
inclusion in the final report. Identity of the vector will be assessed in the Sponsor’s laboratory at 
UCLA, by sequencing the vector plasmid.  Physical titer of the lentiviral vector will be assayed 
in the Sponsor’s laboratory at UCLA. All information will be provided in a Certificate of 
Analysis (COA) or equivalent analysis report.  Reports will be compiled and included in the final 
report. 
 
Reserve Sample Collection for Archive 
 Lin- cells transduced with LV-NY-ESO-1 TCR/sr39TK, at least 2 aliquots with at least 
0.5 x 106 cells each stored in Liquid Nitrogen (test article 1).  
 Lin- cells mock transduced, at least 2 aliquots with at least 0.5x 106  cells each stored in 
Liquid Nitrogen (control article). 
 T cells transduced with RV-NY-ESO-1 TCR, at least 2 aliquots with at least 2 x 106 cells 
each stored in Liquid Nitrogen (test article 2). 
 T cells mock transduced, at least 2 aliquots with at least 2 x 106 cells each stored in 
Liquid Nitrogen (control article) 
Reserve samples will be archived no later than 30 days following the completion of the study. 
 
 
10.0 TEST SYSTEM 
 
Donor Species and Strain: Species:  Mouse, (Mus musculus)  
Strain:  HLA-A2.1/Kb  
125-235 female mice will serve as donors. The donors will 
be 4-12 weeks of age at the time of tissue harvest. 7-12 
mice will be used as donors for T cell and 35-65 mice will 
be used as donors for Lin- cells in each experiment (see 
tables 1-2). 
 
Note:  Additional animals will be bred in case additional 
donors are needed.  Additional mice may be required based 
on the yield of cells from the initial tissue harvest. 
  
Recipient Species and Strain: Species:  Mouse, (Mus musculus)  
Strain:  HLA-A2.1/Kb  
Projected use of 110-200 mice (approximately 50% males 
and 50% females) will be assigned to the study.  Additional 
mice may be added depending on external variables (eg. 
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health issues prior to the administration of the test and 
control articles or failed intravenous administration of the 
test and control articles).  Experiments and cohorts are 
described in Tables 1-2 (see below).  Recipient Mice will 
be 8-14 weeks of age at the time of transplant and at a 
minimum weight 18g for females and 20g for males.   
 
Animal Source: HLA-A2.1/Kb mice (recipient and donors) obtained from 
the Radiation Oncology Department Breeding Colony 
maintained at UCLA. This colony has been tested for the 
HLA-A2.1/Kb transgene expression by HLA-A2.1 staining 
by flow cytometry. The colony is maintained in a 
homozygous condition. Test animals will be assessed for 
HLA-A2 expression at the 3 month time point.   
Any mouse that is not in optimal health as defined by a pre-
study physical examination will not be included in the 
study. 
 
11.0 ANIMAL HUSBANDRY 
 
Housing: Mice will be housed in individually ventilated, irradiated, 
disposable cages (Innovive Inc. San Diego, CA) supplied 
with HEPA filtered air.  The cages will be filled with 
certified ALPHA-dri® Plus irradiated bedding (Newco, 
Rancho Cucamonga, CA). Males and females will be 
housed separately.  The cage density will be 4 mice per 
cage unless animals need to be separated due to fighting or 
health concerns.  
 
 
Acclimatization Period: 1-3 weeks.  The acclimation period will start once the 
recipient mice are moved to the test facility (BSRB-B60C, 
Biological Sciences Research Building).  The mice (all 
cohorts) will receive amoxicillin treated water (at a final 
concentration of 0.25 mg/ml) and certified irradiated rodent 
diet at this time.  The age range of the hosts will be 
maintained independently of the acclimatization time.  
 
Food: The mice will be fed certified, irradiated rodent diet 
(LabDiet inc., Cat# 5K75, LABDIET ADVANCED 
PROTOCOL CERTIFIED PICOLAB RODENT 20%, 
Newco, Rancho Cucamonga, CA) ad libitum.  The 
certificates of analysis for the food will be archived as part 
of this study. 
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Water: The mice will be provided with non-acidified ultrapure 
water (tested and certified), delivered in pre-filled amber 
tint mouse water bottles (Aquavive®, Innovive Inc. San 
Diego, CA) ad libitum.  The certificates of analysis for the 
water will be archived as part of this study.  The water will 
be supplemented with amoxicillin (0.25 mg/ml) for the 
duration of the study.  Amoxicillin is a broad-spectrum 
antibiotic that treats a wide array of bacterial infections and 
is commonly given prophylactically to irradiated mice.  
The Amoxicillin is pharmaceutical grade as required by the 
Guide for the Care and Use of Laboratory Animals 
(Guide), Eighth Edition (National Research Council 2011). 
 
Contaminants No known contaminants are present in the diet, water, or 
bedding (if applicable) at levels that might interfere with 
this study.  The feed, bedding and water will be certified by 
the vendor prior to shipment to the test facility and will 
meet the requirements in accordance with the United States 
Food and Drug Administration (FDA): Good Laboratory 
Practice (GLP) for Nonclinical Laboratory Studies, Code of 
Federal Regulations, Title 21 Part 58.  The certificates of 
analysis for these products will be archived as part of this 
study. 
Personnel All personnel handling the animals will have received 
training in the specific GLP Study Protocol and in the GLP 
regulations. Husbandry staff will follow the procedures 
outlined in the approved DLAM SOPs.  
Room maintenance Animal room maintenance will be in accordance with 
approved DLAM SOPs.  
  
Environmental Conditions:  
Room air, temperature and relative humidity: 
Mice will be housed in individually ventilated racks. The rack air is HEPA filtered via the rack 
blowers. Room temperature will be maintained between 20-26°C (68-79°F) monitored and 
recorded daily. Room humidity will be maintained between 30-70% and will also be monitored 
and recorded daily. The test facility is an AAALAC accredited facility and meets all air quality 
standards stated in the Guide for the Care and Use of Laboratory Animals (Guide), Eighth 
Edition (National Research Council 2011). All facility maintenance and calibration records for 
DLAM will be maintained by DLAM and will not be archived as part of this study.  Records of 
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the temperature, humidity and light cycle for the test facility (BSRB, B60C) will be filed as part 
of this study.  
Light:  
An automatically-controlled 12-hour light: 12-hour dark fluorescent light cycle will be 
maintained. Each dark period will begin at 18:00 hrs PST (+/- 15 minutes).  Light will be 
monitored and records will be filed as part of the study.   
Health Status:  
 
All mice utilized for this study were produced onsite in the 6V-CHS, Radiation-Oncology 
Rodent Breeding Facility.  This facility is a barrier facility with restricted access. All caging, 
feed and water are autoclaved and all personnel entering the facility are dressed in sterile 
personal protective equipment (PPE: jumpsuit, shoe covers, mask, head cover and sterile gloves). 
All animals are maintained in a ventilated rack with HEPA filtered supplied air and handled 
under laminar flow changing hoods. The mice are tested for all major murine pathogens 
biannually and the colony is maintained as a Specific Pathogen Free (SPF) colony. Health 
reports from the breeding colony for the previous 12 months from the date of study initiation will 
be filed as part of this study and will serve as an indicator of health status for the mice utilized on 
this study. The recipient mice will be moved from the breeding colony in sterile cages and 
transferred into irradiated, sterile, disposable cages upon arrival to the test facility in the BSRB 
building (room# B60C).  All personnel entering the test facility will also be required to dress in 
sterile PPE (jumpsuit, shoe covers, mask, head cover and sterile gloves).  No other animals will 
be housed in the test facility with the test animals.  All mice will only be handled under a 
certified biological safety cabinet for all procedures including cage changing.  No sentinel mice 
will be maintained in the animal holding room in accordance with DLAM policy in bio-
containment areas. No sentinel mice will be maintained in the animal holding room in 
accordance with DLAM policy in bio-containment areas. Environmental monitoring will be 
monitored according to DLAM SOPs.    
 
12.0 EXPERIMENTAL DESIGN 
 
Cell Harvest and Transduction for Adoptive T-Cell Transfer  
 
The spleens from the donor mice will be harvested and dissociated to obtain single cell 
splenocyte suspensions.  T cells will be isolated using the mouse EasySep Mouse T cell Isolation 
Kit with manual separation (StemCell Technologies, Vancouver, Canada), or equivalent kit.  
Purity will be determined by flow cytometry (CD3 staining). The cells will only be used for this 
study if the purity of CD3 positive cells is higher than 75%. Viability and cell number will be 
assessed using an automatic cell counter or a manual counting method. T cells will be activated 
by co-culture with CD3/CD28 activating beads (e.g. Dynabeads Mouse T-Activator CD3/CD28 
for T-Cell Expansion and Activation, Life Technologies, Carlsbad, CA) for 20-28 hours.  Cells 
then will be transduced with an ecotropic retrovirus encoding NY-ESO-1 TCR by spinoculation 
on retronectin-coated plates, and expanded for 3 days prior to administration of the cells to the 
recipient mice. Sterility and mycoplasma presence will be tested in the cell media, endotoxin 
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level and vector copy number (VCN) will be determined directly in the cell mixtures (described 
in Tables 1-2) on the day of cell administration. Cells will be kept in culture for 2 weeks and 
transduction efficiency will be determined by ddPCR using primers specific for the retrovirus 
transgene. The 2 week culture is necessary to dilute out the unintegrated vector. Transduction 
efficiency will also be determined by surface and intracellular TCR staining at least 6 days after 
transduction. 
   
 
Cell Harvest and Transduction for Stem Cell Transplant 
 
Donor mice will be euthanized and bone marrow from femurs and tibias will be harvested.  
Enrichment of Lineage negative (Lin-) cells will be performed using The EasySep™ Mouse 
Hematopoietic Progenitor Cell Enrichment Kit with manual separation (StemCell Technologies, 
Vancouver, Canada) or equivalent kit. Purity and quality of the cells will be determined by flow 
cytometry (Lin-, Sca-1 and c-kit staining), cells will be used for this study if the percentage of 
Lin- cells is higher than 25%. Viability and cell number will be assessed using an automatic cell 
counter or a manual counting method.  Lin- cells will be prestimulated with cytokines for 16-24 
hours, transduced with lentivirus encoding NY-ESO-1 TCR/sr39TK and expanded for an 
additional 16-24 hours prior to administration to the recipient mice. Sterility and mycoplasma 
presence will be tested in the cell culture media. Endotoxin level and VCN will be measured 
directly using the T cell and Lin- cell mixtures (described in Tables 1-2) prepared the day of cell 
administration. Transduction efficiency will be determined after 2 weeks in culture by digital 
droplet PCR (ddPCR) using primers specific for the lentiviral psi packaging signal. The 2 week 
culture of cells is necessary to dilute out the unintegrated vector. The target vector copy number 
(measured after a 2 week culture) per cell is 0.6-3. Transduction efficiency will also be 
determined by intracellular TCR staining at least 4 days after transduction. 
 
Irradiation of Recipient Mice 
Before cell transplant, mice in cohort B, C, D and E, according to the experimental design (see 
Tables 1-2), will be irradiated with a lethal dose of 900 cGy in the J.L. Shepherd Mark I 
Irradiator in the Biomedical Science Research Building (BSRB)  mouse facility. Mice will be 
transplanted with donor cells within 24 hours post irradiation. Additional mice will be irradiated 
to be used in the event of a failed intravenous injection of the cell treatment. These additional 
mice will have unique IDs and all procedures will be documented. These mice will be euthanized 
on the day of administration if they were not needed for the study. 
Cell Transplantation 
T cell and Lin- cell mixtures will be injected into the tail vein of recipient HLA-A2.1/Kb mice 
according to the groups outlined in Tables 1-2.  Cells will be combined and administered 
together as a single injection to reduce variability in injection efficiency, and reduce pain and 
anxiety for the animals. 
Experimental Design (Summarized in Tables 1-2) 
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Due to the large number of animals, the study will be divided into three experiments. Two 
experiments (1 and 2) will include all groups with 4 males and 4 females in each group. The end 
point for these experiments will be 3 months after the transplant. The last experiment (3) will 
include all groups with 3 males and 3 females per group and the end point will be at day 5 after 
transplant. 
 
Table 1.  Experiments 1 and 2 
 
Group XRT 
Treatment 
3 Month# 
T cells HSCs 
Cohort 
A 
No No No 4M/4F 
Cohort 
B 
Yes 
2-3 x 106  Mock 
Transduced T cells 
1-2 x 106  Mock Transduced 
Lin- cells 
4M/4F 
Cohort 
C 
Yes 
2-3 x 106  Mock 
Transduced T cells  
1-2 x 106 TCR Transduced 
Lin- cells 
4M/4F 
Cohort 
D 
Yes 
2-3 x 106 TCR 
Transduced T cells 
1-2 x 106  Mock Transduced 
Lin- cells  
4M/4F 
Cohort E Yes 
2-3 x 106 TCR 
Transduced T cells 
1-2 x106 
TCR Transduced Lin- cells 
4M/4F 
 
 
Table 2.  Experiment 3 
 
Group 
 
XRT 
 
Treatment 
Day 5 
 
T cells HSCs 
Cohort 
A 
No No No 3M/3F 
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Cohort 
B 
Yes 
2-3 x 106  Mock 
Transduced T cells 
1-2 x 106  Mock Transduced 
Lin- cells 
3M/3F 
Cohort 
C 
Yes 
2-3 x 106  Mock 
Transduced T cells  
1-2 x 106 TCR Transduced 
Lin- cells 
3M/3F 
Cohort 
D 
Yes 
2-3 x 106 TCR 
Transduced T cells 
1-2 x 106  Mock Transduced 
Lin- cells  
3M/3F 
Cohort 
E 
Yes 
2-3 x 106 TCR 
Transduced T cells 
1-2 x106 
TCR Transduced Lin- cells 
3M/3F 
 
 
#3 months = 90 days ± 7 days to accommodate scheduling with external test sites and allow 
enough time to process and ship all samples. Euthanasia at this time point will be split in two 
consecutive days due to the large number of animals used.  
Mice from cohort A will not be irradiated.  XRT = Irradiation. 
 
If for any reason, on the day of transplant, there are not enough cells for all mice, the number of 
mice per group will be reduced, accordingly. The reduction in the number of mice will be 
compensated in the following experiment, if possible.  This will be documented in the study 
records.  
 
The numbers of mice proposed in Tables 1-2 are based on our primary comparison at 3 months 
post-transplant, in which we will evaluate the key parameters of hematology between Cohort C 
and Cohort E. According to our preliminary data, white blood cell (WBC) count in Cohort C had 
a mean of 6.5K/uL with a standard deviation of 1.7 K/uL.  An equivalence test of means using 
two one-sided tests with sample sizes of N=16 (4M/4F each in Experiment 1 and Experiment 2) 
animals in each of Cohort C and Cohort E achieves 89% power at 5% significance level when 
the true difference in mean WBC between the two groups is 0.0 K/uL, the standard deviation is 
1.7 K/uL, and the equivalence limits are -2.0 K/uL and 2.0 K/uL (corresponding to +/- 30% of 
the Cohort C). We are confident that with the proposed numbers of animals we will have 
sufficient power to analyze the data. With the numbers proposed in Table 3, a sample size of 6 in 
each cohort produces a two-sided 95% confidence interval with a distance from the mean of 
VCN to the limits that is on the order of 1.0XSD (standard deviation). 
 
Mice from each cohort will be euthanized at 5 days (experiment 3) and at 3 months (experiment 
1 and 2) post-transplant. The T cell signal following T cell transplantation has been demonstrated 
to peak at 5 days in the mouse (Koya, et al.  2010). Based on our previous experience, the 
repopulation of the peripheral blood  cells by progeny derived from transplanted HSCs should 
occur by 3 months in mice. Based on previous experiments, 1-2 x 106 –Lin- bone marrow cells 
are needed for successful engraftment and survival of lethally irradiated mice (unpublished data). 
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And at least 2-3 x 106 T cells are required for a successful adoptive cell transfer in mice based on 
previous experience.  
 
This study will determine whether the co-administration of HSCs and T cells transduced with 
lentiviral and retroviral vectors expressing the same NY-ESO-1 TCR alters the differentiation of 
different hematological cell types.  In addition, this study will determine whether the co-
administration of both cell types has an adverse effect on engraftment of HSCs and on 
persistence of T cells and HSCs derived progeny. 
 
Studies using HSC transplantation need to take into account potential toxicity from the 
procedures, therefore we will compare the experimental groups to mock transduced mice. In 
addition, there is the potential for the acceleration of T cell development by introduction of a pre-
arranged TCR thereby increasing T cell proportions in transduced mice. This potential 
phenomenon will also be addressed in this study.  
 
Endpoints 
 
Peripheral blood, bone marrow and splenocytes will be harvested at 5 days and 3 months post 
transplant.  The following endpoints will be assessed:   
 
Day 5: 
 Presence of transduced T cells in splenocytes and blood using ddPCR specific retroviral 
element primers 
 Presence of transduced HSCs in bone marrow and blood using ddPCR specific for the 
lentivirus packaging signal (psi). 
 Hematology to confirm myelodepletion 
 Body weight 
 Spleen weight 
 Clinical observations 
 
3 Months:  
 Engraftment of transduced HSCs and persistence of their progeny in the bone marrow, 
spleen and blood using ddPCR specific for lentiviral elements. 
 Persistence of the transduced T cells in the spleen, the bone marrow and the blood using 
ddPCR specific for the retroviral vector. 
 Assessment of cell lineages in peripheral blood via Cell blood counts and differential 
counts (hematology)  
 Assessment of engraftment of transduced HSCs by flow cytometry in bone marrow cells 
using antibodies to detect intracellular TCR and surface stem cell markers (see section 
15.13). 
 Assessment of transduced T cell and transduced HSC progeny by flow cytometry in the 
spleen using antibodies to detect intracellular TCR and T cell, B cell and granulocyte 
surface markers (see section 15.13).  
 Confirmation of transgenic mouse phenotype by surface HLA-A2 staining in the 
splenocytes  
 Body weight 
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 Clinical observations 
 Gross pathology (with selected organ weights, see Table 4)  
 Histopathology (of protocol-specified tissues, see Table 4) 
 Serum chemistry 
 
13.0 ANIMAL IDENTIFICATION, RANDOMIZATION AND ASSIGNMENT 
 
Recipient mice will be acclimated for 1-3 weeks in room BSRB-B60C following the transfer 
from the 6V-CHS UCLA colony.  After transfer, all mice will be identified with a unique 
identification (ID) number and a cage number. These numbers will be consecutive throughout 
the whole study. Mice will be ear punched for identification. Mice will be marked with a sharpie 
on the tail as a secondary method of identification after therapy administration. Prior to 
irradiation and transplantation of cells, the recipient mice will be randomized by gender and by 
cage into treatment groups. Cages will be randomized into treatment groups using the random 
numbers function in an excel file. Mice will be weighed and clinical observations will be 
documented before the treatment starts. Any mouse that is not in optimal health condition before 
the treatment starts will be excluded from the study, euthanized and substituted with a healthy 
mouse.  Additional mice (not assigned to any group) will be irradiated. These mice will only be 
used in case of a failed cell injection and euthanized if not needed after cell administration. Any 
mice receiving a failed cell administration will be euthanized as well. All procedures will be 
appropriately documented.  
 
14.0 TRANSPLANTATION 
 
Ex vivo Transduction of Lineage Depleted Mouse Bone Marrow Cells and T cells 
 
Isolated T cells will be cultured and transduced with retrovirus encoding NY-ESO-1 TCR (see 
6.0 Experimental Design above).  Lin- cells will be cultured and transduced with lentivirus 
encoding NY-ESO-1 TCR/sr39TK (see 6.0 Experimental Design above). 
 
On the day of administration, cells will be collected and washed. Cell counts and viability will be 
recorded. Viability over 65% is required to continue with the cell administration. Cells will be 
resuspended at the correct concentration and mixed according to Tables 1-2. Viability of cell 
mixtures will be measured before and after treatment administration to assess stability. The 
culture medium of transduced and mock Lin- and T cells will be tested for sterility and 
mycoplasma (by biochemical test). Each cell mix (according to Tables 1-2) will be tested for 
endotoxin (limit per treatment 5EU/Kg). Sterility testing will be performed at Labs, Inc. 
(Centennial, CO) in accordance with their SOPs. Mycoplasma and endotoxin testing will be 
performed in the Ribas lab. Lentivirus and retrovirus VCN will be determined in the cell 
mixtures to confirm that equivalent amounts of each cell type have been mixed appropriately.  
Transduction efficiency in Lin- cells and T cells will be tested for vector copy number (VCN) 
after culture for a period of 12-14 days to dilute out unintegrated vector.   
 
Shipping:  Cell media samples will be shipped from UCLA to Labs, Inc. for sterility testing. 
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Monroe A. Burgess, CTBS 
LABS INC  
6933-B S Revere Pkwy  
Centennial, CO 80112 
Telephone No.: 520.990.1573/ 800.321.6088 
E-mail: Monroe_Burgess@labs-inc.org  
 
Acceptance criteria: 
 
Test  Item Acceptability Criteria 
T cell purity >75% 
Lin- purity >25% 
Lin- VCN (2 weeks after culture) 0.6-3 
T cell viability (day of administration) > 65% 
Lin- cell viability (day of administration) > 65% 
Mycoplasma Negative 
Endotoxin <5EU/Kg 
Sterility Negative 
 
T cell and Lin- purity and viability results will be available before treatment administration. If 
any of the parameters fail, the study director and the sponsor will determine if the experiment 
shall proceed. Animals will be transplanted prior to the availability of VCN, mycoplasma, 
endotoxin and sterility data. If any of the parameters fail, the study director and the sponsor will 
determine if the experiment should be terminated or will proceed. Since mouse cells do not 
freeze/thaw well and lyse readily when thawed and since it takes time to evaluate transduction 
efficiency and sterility, we plan to inject cells fresh in this study at the risk of having to euthanize 
animals if the results do not meet the release criteria.  
 
15.0 OBSERVATIONS, MEASUREMENTS, AND TERMINATION 
15.1 Clinical Observations and health checks 
 
During the acclimation period and throughout the study, the animals will be observed daily by 
animal care staff for morbidity and mortality.   
 
Daily general health checks are performed by DLAM personnel per approved DLAM SOPs.  
Clinical observations will be made by the Ribas lab study personnel at least twice a week 
including the day of euthanasia and more frequently if deemed necessary according to the mouse 
health status. Observations will include changes in skin and fur, eyes, mucous membranes and 
other signs of respiratory, circulatory and neurological dysfunction.  Animals having ruffled fur, 
hunched posture, severe dyspnea, self-mutilation and/or reluctance to move upon stimulation 
will be evaluated and considered for humane euthanasia.  Additional actions will be made by 
study personnel if clinical signs warrant such as necropsy. All decisions concerning the health 
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and wellbeing of the animals and any subsequent decision to euthanize them will also be made 
by the Study Director in consult with the veterinarian. 
 
Several complications associated with the myelodepleting irradiation and the bone marrow 
transplant are expected. Irradiation causes animal morbidity through tissue damage, which in 
turn elicits an inflammatory response.  The symptoms of myeloablation in mice is weight loss 
(greater than 20% in some individuals), general lethargy, dehydration (ridged skin, spikey fur, 
sunken eyes). Mice that survive lethal total body irradiation and are able to reestablish their 
hematopoietic system after a bone marrow transplant will exhibit the symptoms of myeloablation 
but will recover during weeks 4-6 after irradiation.  Recovery (a successful bone marrow 
transplant) is physically manifested by weight gain, return to normal activity levels, normal food 
and water consumption, normal defecation and urination volumes.  The only residual effect that 
may be observed in a small percent of survivors (post irradiation) is a change in fur color from 
black to white or gray.  This change in coloration may be isolated in patches or may involve the 
animal’s entire body. In some cases, mice never recover, these mice will be euthanized.  
 
 
15.2 Body Weight 
 
Body weight will be recorded for all mice the day prior to irradiation, three times weekly until 
day 60 after bone marrow transplant, and then twice weekly until the time of scheduled 
euthanasia.  Body weight will be recorded on additional days by study personnel if clinical signs 
warrant.  Body weight on the day of euthanasia will be recorded prior to blood collection and 
necropsy. 
 
15.3 Evaluation of Engraftment and Persistence of Gene Modified Cells Post 
Transplant 
 
Mice in cohorts A-E will be euthanized at 5 days and 3 months post transplantation.   
 
Day 5: 
 
 Presence of transduced T cells:  Splenocytes and peripheral blood will be harvested and 
VCN will be determined by ddPCR using primers specific for the retrovirus. 
 Presence of transduced HSCs: Bone marrow and peripheral blood will be harvested and 
VCN will be determined by ddPCR using primers specific for the lentivirus Psi signal. 
 
3 Months:  
 
 Engraftment/persistence of transduced HSCs and their progeny:  Bone marrow, 
splenocytes and blood will be harvested, and VCN will be determined by ddPCR using 
lentiviral element primers. 
 Persistence of transduced T cells:  Bone marrow, splenocytes and blood will be 
harvested, and VCN will be determined by ddPCR using retroviral element primers. 
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 Engraftment of transduced HSCs will be assessed by intracellular TCR and surface stem 
cell marker staining by flow cytometry of bone marrow cells (see section 15.13). 
 
15.4 Evaluation of Hematopoietic Cell Lineage Development Post Transplant   
 
Complete blood counts (CBC) with differential counts will be assessed in the peripheral blood 
from mice at 5 days and 3 months after transplant.  Untreated mice (cohort A) will be also 
euthanized at 5 days and 3 months post transplantation, and peripheral blood will be collected for 
comparison to the other groups. CBC data at day 5 will be used to confirm myelodepletion. 
Hematology data 3 months after bone marrow transplant will be used to confirm the expected 
differentiation of the HSC into all blood cell subsets. CBC includes: WBC; relative and absolute 
values for neutrophils, lymphocytes, monocytes, eosinophils, and basophils; RBC, Hb, HCT, 
MCV, MCH, MCHC, RDW, PLT and MPV. Blood will be sent to Quality Vet Lab (Davis, CA) 
for CBC assessment to be performed under GLP regulations per their SOPs. 
 
To assess the differentiation of transduced HSC into the different hematopoietic cell lineages, 
intracellular TCR together with T cell, B cell and granulocyte surface markers will be stained 
and analyzed by flow cytometry in splenocytes from mice euthanized 3 months after transplant 
(section 15.13).   
 
15.5 Necropsy and Tissue Harvest 
 
 Mice will be euthanized using CO2 inhalation and subsequent exsanguination.   
 A body weight will be recorded for each animal before euthanasia except as noted below  
(Unscheduled termination).   
 Blood will be collected via cardiac puncture.  Blood will be distributed and processed for 
hematology, chemistry and VCN as follows.  Briefly, whole blood (minimum 350 µL at 
day 5 after transplant and 250µL at 3 months after transplant) will be collected in EDTA-
containing tubes for evaluation of complete blood count (CBC) with differentials (see 
table 5). An aliquot of 100µL will be collected and transferred into an Eppendorf tube for 
VCN analysis.  During the necropsy at 3 months after transplant, the remaining blood 
will be placed in a serum separator tube for serum chemistry evaluation. At least 400 µL 
of total blood is needed for this purpose. Chemistry analysis includes: ALT, AST, BUN, 
CRE-S, CK, ALP, BUN/CRE-S, GLU, ALB, TPRO and TBILI, GLOB and A/G. If 
enough blood is not obtained due to technical issues, samples will be distributed 
following the prioritization list stated in section 15.8. Also if there is not a sufficient 
amount of blood for hematology analysis, a white blood count estimate and a differential 
will be obtained from a blood smear (see section 15.10). 
 Necropsies will consist of a complete external and internal examination including 
examination of body orifices (ears, nostrils, mouth, anus, etc.) and intra-cranial, thoracic 
and abdominal organs and tissues.  The organs to be weighed and collected during 
necropsy are listed in Table 4.  All gross findings will be recorded in descriptive terms 
including location, size, shape, color, consistency and number. Necropsies will be 
performed by trained prosectors. 
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15.6 Scheduled Termination 
 
Day 5: 
 A complete necropsy will NOT be performed. 
 Blood will be collected for CBC. 
 Blood, splenocytes and bone marrow will be harvested for VCN assessment. 
 
3 Months: 
 A complete necropsy will be performed on all animals (see section 15.5). Tissues will be 
processed and stained for histopathological examination by Histo Tox Labs, (Boulder, 
CO) as a GLP compliant study according to their SOPs and analyzed by anatomic 
pathologist Brad Bolon, DVM, MS, PhD, an ACVP board-certified veterinary 
pathologist.  All tissues listed in Table 4 will be fixed by immersion in GTF™, Formalin 
Substitute solution for histopathology and send within a week to HistoTox Labs for 
further processing. 
 Blood will be collected for serology (CBC and serum chemistry) and sent to Quality Vet 
Lab (Davis, CA). 
 Blood, splenocytes and bone marrow will be harvested for VCN assessment. 
 Splenocytes and bone marrow will be harvested for flow cytometry. 
 
15.7 Unscheduled Termination and Death 
 
Animals found dead:   
When an animal is found dead in the cage, the carcass will be bagged, labelled with the 
animal’s identification information, Sponsor Name, GLP Study Number, and stored in a 
refrigerator in B70B hallway until it can be necropsied by Ribas Lab trained personnel.  The 
staff member who finds the dead animal will notify the Study Director immediately via 
phone and document notification of finding with an email to the Study Director.   
 Since the exact time of death is unknown a modified necropsy will be performed.  Blood 
samples will be omitted from the necropsy process of mice found dead in the cage.  
 All organs listed in Table 4 will be collected if possible and fixed in GTF™, Formalin 
Substitute solution. These organs will be shipped for further processing to HistoTox Labs 
together with all the samples from scheduled necropsies. 
 The carcasses will be kept in GTF™, Formalin Substitute solution and archived. 
 Body and organ weights will not be assessed. 
Animals euthanized prior to the scheduled necropsy: 
Animals will be euthanized prior to the scheduled necropsy if clinical signs warrant it. 
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 For animals that need to be euthanized for humane reasons before the scheduled necropsy 
end point, a full necropsy will be performed whenever possible as described in section 
15.5, and justification will be documented if necropsy is not possible. Samples for VCN 
analysis in blood, splenocytes and bone marrow cells will only be collected if trained 
personnel are available. Flow analysis will not be performed in these animals. If an 
animal is found moribund on a Friday, the weekend or a holiday blood samples will be 
refrigerated, a blood smear will be performed and kept at room temperature and serum 
samples will be kept at -80ºC. All these samples will be sent as soon as possible to 
Quality Vet Labs. If blood samples are not viable by the time it can be analyzed, a white 
count estimate and a differential will be assessed from the blood smear.  
 
15.8 Tissue Sample Distribution 
 
The distribution of tissue samples is summarized in Table 4. All major tissues from all 
necropsied mice will be harvested and analyzed as described in table 4 and following sections 
15.9, 15.12 and 15.13.    
 
Table 4.  Distribution of Tissues at Necropsy for All Mice 
 
Tissues for 
Evaluation 
Weightb Histopathology ddPCR Flow 
Spleen 
Collect sterilely 
X 
Whole spleen 
Xc 
 
Xa,c 
 
Xa,c 
 
Right Femur 
&Tibia 
Collect sterilely 
NA NA Xa  
 
Xa  
 
Sternum & Xiphoid 
process 
NA X, Decalcified   
Thymus & 
Associated Fat Pad 
NA X   
Lungs & Trachea NA X   
Larynx &Thyroid 
Gland 
NA X   
Heart X X   
Liver with Gall- 
Bladder attached 
X X + Gall bladder   
Pancreas NA X   
Stomach NA X   
Duodenum NA X   
Ileum NA X   
Jejunum NA X   
Cecum NA X   
Colon NA X   
Mesenteric Lymph NA X   
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Nodes 
Adrenals NA X   
Kidneys X 
Weigh  
together 
X, Right cross section, 
Left longitudinal 
section 
  
Urinary Bladder X X   
Ovary-Female 
 
X X   
Uterus-Female  X   
Testes with 
epididymis-Male 
X X   
Seminal vesicles, 
Prostate Glands 
Coagulating Gland-
Males 
 
NA X   
Eye with optic 
nerve 
NA X   
Brain (without 
olfactory bulbs) 
Xd X   
Skin & 
Mammary Glands-
(mammary glands 
for Females only) 
NA X   
Left Quadriceps 
Femoris 
NA X   
Left Femur &Tibia NA X, Decalcified   
Remainder of the 
Carcass/Tissues 
NA NA   
Gross lessions 
(if observed) 
NA X   
a Cell suspensions will be prepared and numbers and viability of cells will be assessed using an 
automated or manual cell counter.  DNA will be isolated from approximately 1-5 x 106 cells for 
ddPCR analysis. Approximately 1-6 x 106 will be used for flow analysis.   
b Weight will be recorded if the mice are terminated and not found dead. 
c One half of the sample is designated for ddPCR and flow and the other half will be processed 
for histopathology. 
d Brain will be sectioned according to Society of Toxicologic Pathology recommendations 
(Bolon et al 2013) 
NA. Not assessed. 
 
For tissues with limited materials, the testing will be prioritized as follows: 
 
Peripheral Blood: 
 
1. Hematology 
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2. Vector copy number (VCN) 
 3.   Serum chemistry 
 
Spleen: 
 
 1.  ddPCR 
 2.  Histopathology 
            3.  Flow cytometry 
 
Bone Marrow: 
 
 1. ddPCR 
 2.  Histopathology 
3. Flow cytometry 
 
15.9 Histopathology 
 
Tissues to be shipped to Histo Tox Labs, Inc. (Boulder, CO) and processed for histopathology 
according to GLP regulations per HistoTox SOPs on all mice in all groups are listed in Table 4.  
Tissues will be shipped in GTF™, Formalin Substitute solution.  Remaining carcasses will be 
archived. Fixed tissues will be trimmed and embedded in paraffin and processed for 
histopathology.  Slides will be analyzed by pathologist Dr. Brad Bolon either at the Histo Tox 
Labs facility (Boulder, CO) or at his office (Longmont, CO), as defined by availability of space 
at the Histo Tox Labs site when the slides are completed.  
 
Shipping Tissues will be shipped from UCLA to Histo Tox Labs, Inc for 
processing into slides. 
Jon Bishop 
HistoTox Labs, Inc. 
2108 55th St, Suite 110 
Boulder, CO 80301 
Telephone No.: 303-633-5401 
E-mail: jbishop@histotoxlabs.com  
 
Slides and blocks will be maintained at Histo Tox Labs, Inc. The 
anatomic pathologist will review the slides either at HistoTox Labs, 
Inc or if necessary transport them to his nearby office. 
 
Brad Bolon, DVM, PhD 
GEMpath, Inc. 
1100 East 17th Avenue, Unit M202 
Longmont, CO  80504 
Telephone No.: 720-209-1105 
E-mail: bradgempath@aol.com 
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Following microscopic evaluation procedures, slides and blocks will 
be returned to the test facility prior to finalization of the report.  
Slides will be returned to the following address. 
 
Cristina Puig Saus, PhD 
David Geffen School of Medicine at UCLA 
Department of Medicine 
Division of Hematology/Oncology 
10833 Le Conte Ave. 
Factor Building 9-666 
Los Angeles, CA  90095 
E-mail: cpuigsaus@mednet.ucla.edu 
Telephone No: 310-267-0596 
 
  
The Principal Investigator for Anatomic Pathology will be responsible for all delegated phase 
activities and will submit a pathology sub-report from the data generated including hematology 
and serum chemistry interpretation, to the Study Director for inclusion in the final study report.  
The pathology report also will include a signed Good Laboratory Practices compliance statement 
and a Quality Assurance Statement. 
 
15.10 Hematology and Serum Chemistry 
 
Blood (as much as possible) will be collected via cardiac puncture prior to initiation of the full 
necropsy. Hematology and serum chemistry evaluations will be performed on blood samples 
collected from all designated mice scheduled for euthanasia and will be attempted on moribund 
animals (refer to section 15.7, Unscheduled Termination and Death for details).   Blood will be 
collected, shipped and analyzed by Quality Vet Lab (Davis, CA) according to GLP regulations 
per Quality Vet Lab SOPs.  For hematology analyses, whole blood will be placed into one tube 
per animal containing ethylene diamine tetraacedic acid (EDTA) as an anticoagulant.  A blood 
smear will be prepared from each blood sample.  Hematology parameters to be analyzed are 
shown in Table 5. If there is not enough sample to perform a hematology assessment, a 
differential blood count will be performed with the blood smear. For Serum chemistry blood will 
be placed in a serum separator tube and centrifuged to obtain the serum.  
If enough blood can not be obtained for all analysis, then the priority listed in section 9.7 will be 
applied.   
 
Day 5: 
 
Only hematology samples will be collected at Day 5 termination.   
 
3 Months: 
 
Both hematology and serum chemistry will be collected at the 3-month termination.      
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Table 5.  Hematology Parametersa 
 
Parameter Abbreviation Units 
Red Blood Cell Count RBC 106/µL 
White Blood Cell Count WBC 103/µL 
Hemoglobin HGB g/dL 
Hematocrit HCT % 
Mean Corpuscular Volume MCV fL 
Mean Corpuscular 
Hemoglobin Concentration 
MCHC g/dL 
Mean Corpuscular 
Hemoglobin 
MCH Pg 
Red Cell Distribution Width RDW % 
Platelet Count PLT 103/µL 
Mean Platelet Volume MPV fL 
Relative Differential White Blood Cell Count 
Neutrophils NEUT % WBC 
Lymphocytes LYM % WBC 
Monocytes MONO % WBC 
Eosinophils ESO % WBC 
Basophils BASO % WBC 
Absolute Differential While Blood Cell Count 
Neutrophils Abs. NEUT 103/µL 
Lymphocytes Abs. LYM 103/µL 
Monocytes Abs. MONO 103/µL 
Eosinophils Abs. EOS 103/µL 
Basophils Abs. BASO 103/µL 
a Abbreviations from the hematology system readout may differ from those listed above, but the 
results will be reported as described above. 
 
For serum chemistry analyses, the remaining whole blood will be placed in a serum separator or 
clot tube for centrifugation to separate cellular and serum fractions.  The serum chemistry 
parameters to be measured or calculated are shown in Table 6. 
 
Table 6.  Serum Chemistry Parametersa 
 
Analyte Abbreviation Units 
Alanine Amino Transferase 
(Alanine Transaminase) - 
Serum 
ALT IU/L 
Aspartate Animo Transferase AST IU/L 
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(Aspartate Transaminase) - 
Serum 
Blood Urea Nitrogen BUN mg/dL 
Creatinine (Serum) CRE-S mg/dL 
Creatinine Kinase* CK IU/L 
Alkaline Phosphatase* ALP IU/L 
Blood Urea 
Nitrogen/Creatinine (Serum)  
(Calculated value) 
BUN/CRE-S None 
Glucose GLU mg/dL 
Albumin ALB g/dL 
Total protein TPRO g/dL 
Bilirubin, Total T BILI mg/dL 
Globulin* GLOB g/dL 
A/G Ratio* A/G - 
a Abbreviations from the chemistry system readout may differ from those listed above, but the 
results will be reported as described above.*If there is not enough serum sample these 
parameters will not be assessed. 
  
Shipping Blood will be shipped from UCLA to Quality Veterinary Laboratory 
for processing. 
Joan Shewmaker CLS, MT(ASCP) 
Manager  
Quality Veterinary Laboratory 
Telephone No.: 530-759-8533 
Fax: 530-759-8553 
E-mail: joan@qualityvetlab.com 
Website: www.qualityvetlab.com 
 
The Principal Investigator for hematology and serum chemistry will be responsible for all 
delegated phase activities and will provide hematology and serum chemistry data to the Study 
Director to send to the anatomic pathologist for interpretation.   
 
 
15.11 Leukocyte Isolation from Spleen and Bone Marrow 
 
Single cell suspensions will be prepared from spleen and from femurs and tibias of all mice for 
ddPCR and flow cytometry if needed (Table 4). Cells will be counted using an automated or 
manual cell counter (hemocytometer), and then DNA will be isolated from 1-5 x 106 cells for 
ddPCR.  The remaining cells will be used for flow cytometry. 
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15.12 ddPCR 
 
DNA will be extracted from blood, spleen and bone marrow following harvest.  ddPCR analysis 
will be used to determine engraftment and persistence using primers that specifically amplify 
retroviral and lentiviral elements.  
 
15.13 Flow Cytometry 
Bone marrow isolated from femur and tibia and splenocytes isolated from spleens of recipient 
mice (at 3 months after injection) will be counted using an automated or manual cell counter.  
Expression of NY-ESO-1 TCR in both cell preparations will be determined by the intracellular 
staining of the beta chain of the NY-ESO-1 TCR (Vb13). Stem cell subsets will be characterized 
by surface staining of Lineage markers, Sca-1, cKit, CD48 and CD150 in bone marrow samples. 
T cell, B cell and granulocyte subsets will be assessed by surface staining of CD3, CD4, CD8, 
NK1, IgM, B220, Gr-1, CD-11b and F4/80 in splenocytes. Also to confirm the transgenic mouse 
phenotype, surface HLA-A2 staining will be performed on splenocytes from each mouse.  
16.0 STATISTICAL ANALYSES 
 
Descriptive statistics including mean, standard deviation, frequency, percentage and range will 
be calculated for quantitative endpoints such as retrovirus/lentivirus VCN measured by ddPCR, 
cell populations characterized by flow cytometry, hematology parameters (Table 5), serum 
chemistry measurements (Table 6) and animals’ body and organ weights. Appropriate summary 
tables, scatter plots and box plots will be presented. Transformation for continuous endpoints 
will be performed as necessary to satisfy normality assumption before testing. Also, 
nonparametric approaches will be investigated as possible alternatives. 
 Primary statistical analyses are listed as follows: 
1) For the evaluation of T cell engraftment, unpaired t test will be performed to compare 
retrovirus VCN between Cohort D and Cohort E in blood and spleen harvested on Day 5 
after transplant.  
2) For the evaluation of HSC engraftment, unpaired t test will be performed to compare 
lentivirus VCN between Cohort C and Cohort E in bone marrow, blood and spleen at 3 
months after transplant.  
3) For the evaluation of the effect of transduced Lin- and T cell co-administration on HSC 
differentiation, unpaired t test will be performed to compare CBC parameters (e.g. RBC, 
WBC, platelets and Hemoglobin) between Cohort C and Cohort E at 3 months after 
transplant.  
 
Effects of Co-administration of T cells and Lin- cells 
Version date 04/27/16  
30 
 
 Secondary statistical analyses are listed as follows: 
1) For the evaluation of survival of transplanted animals, Kaplan-Meier survival curves will 
be plotted for each cohort and log-rank test will be used to compare the survival 
distributions between experimental cohorts. 
2) For the evaluation of T cell persistence, unpaired t test will be performed to compare 
retrovirus VCN between Cohort D and Cohort E in blood and spleen harvested at 3 
months after transplant. 
3) For the evaluation of HSC differentiation, unpaired t test will be performed to compare 
the frequency of the different cell subsets (T cell, B cell and granulocyte) in the Vb13+ 
compartment compared to the whole population in the spleen between Cohort C and 
Cohort E at 3 months after transplant.  
4) For the evaluation of HSC engraftment, unpaired t test will be performed to compare the 
TCR expressing (Vb13+) cells in the bone marrow between Cohort C and Cohort E at 3 
months after transplant.  
An alternative approach for analyzing the aforementioned primary and secondary VCN-related 
endpoints would be to dichotomize the VCNs (e.g. engraftment or not, persistence or not) based 
on the detection limit and Fisher’s exact test will be used to compare the proportion of 
engraftment/persistence between cohorts. 
 As exploratory statistical analyses, multi-factor ANOVA will be used to compare 
between experimental groups while adjusting for gender and possible group*gender 
interaction. To further adjust variations due to individual mice, cages and experiments, a 
multivariate linear mixed model approach will be adopted to include individual 
mice/cages/experiments as random effects 
All statistical analyses will be carried out using SAS version 9.4 (SAS Institute Inc. 2013). 
Analysis results will be included as an appendix to the final report. 
17.0 RECORDS, TEST ARTICLES AND SPECIMENS TO BE RETAINED 
 
Specimens will be identified by study protocol number, experiment number, animal number, 
nature (i.e DNA, blood, etc.) and date of collection. Test and control articles will be identified 
with the protocol number, the experiment, the cell type, transduction status and the date. All test 
articles, controls and specimens will be archived by the sponsor at UCLA for 5 years after IND 
submission.  All raw data and records that would be required to reconstruct the study will be 
maintained by the sponsor at UCLA Ribas Lab archive according to Ribas Lab SOP for at least 5 
years after IND submission.   
 
Records retained will include but not be limited to: 
 
 Study protocols, SOPs, communication logs, completed forms or attachments and all raw 
data. 
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 Personnel records, job descriptions, CVs and training records. 
 Test and control materials 
o Lentiviral and retroviral vector receipt, storage, usage and distribution 
o Lineage depleted cell generation, storage, usage and distribution 
o T cell generation, storage, usage and distribution 
 Facilities 
o Animal room temperature, humidity and light logs 
o Water, feed and bedding analysis 
o Equipment calibration, and maintenance  
o Cold and warm storage records 
 Cell culture and transduction 
o Cell viability prior to transplant 
o T cell and Lin- cell purity 
o Results of ddPCR-evaluation of transduction 
o Sterility, mycoplasma, endotoxin test and VCN 
 In-life phase 
o Animal transfer and disposition 
o Pre-dosing observations and health assessment 
o Animal randomization and identification 
o Body weights, clinical observations and health checks 
o Transplantation records  
o Records of antibiotic treatment delivered to animals 
o Sample collection and hematology/serology results from moribund mice 
 Endpoint data and analyses 
o Blood collection 
o Hematology and serum chemistry 
o DNA extraction and quantity 
o ddPCR results and analyses 
o Flow cytometry 
o Necropsy records 
o Histopathologic analysis records 
 
Test articles, viral vectors and specimens retained will include but not be limited to: 
 Test articles and test controls (Reserve samples, see section 9.0): 
o Lin- cells transduced with LV-NY-ESO-1 TCR/sr39TK, at least 2 aliquots stored 
in Liquid Nitrogen (test article 1).  
o Lin- cells mock transduced , at least 2 aliquots stored in Liquid Nitrogen (control 
article). 
o T cells transduced with RV-NY-ESO-1 TCR, at least 2 aliquots stored in Liquid 
Nitrogen (test article 2). 
o T cells mock transduced, at least 2 aliquots stored in Liquid Nitrogen (control 
article) 
 Viral vectors at least 5 aliquots of each. 
Effects of Co-administration of T cells and Lin- cells 
Version date 04/27/16  
32 
 
 Blood smears, slides, blocks (with paraffin-embedded tissues) and fixed carcasses. 
 All DNA samples. 
 
Reserve samples will be archived no later than 30 days following the completion of the study 
with the submission of the final report. 
 
 
18.0 FINAL REPORT 
 
A complete report of the work performed will be audited by the Quality Assurance Unit (QAU) 
at UCLA.  A comprehensive final report that encompasses interpretation of the results, statistics 
and all other work performed in support of this study will be prepared.  The final draft report will 
be generated electronically.  In addition, the original signed hard copies of the final report 
including all appendices will be generated and archived. 
19.0 QUALITY ASSURANCE 
 
Quality Assurance Unit (QAU) Audits 
 
The QAU at UCLA will audit and issue a Quality Assurance Statement that will include all 
critical phases of the study including: initiation, in-life, pathology, reporting, and the final report.  
The QAU will make critical phase inspections and examine the data to ensure that it is complete, 
consistent and well documented.  The QAU in conjunction with the Study director and 
responsible scientist(s) will formally examine the final report to ensure that it accurately 
represents the raw data collected in the study in accordance with Standard Operating 
Procedures/Protocols, Study Specific Procedures, the Study Protocol and as required by Good 
Laboratory Practice regulations (as applicable). 
 
The QAU at the test sites (Histo Tox Labs, Inc,, and Quality Vet Lab) will be responsible for 
quality assurance at their respective facilities to comply with GLP regulations and a Quality 
Assurance Statement will be issued and included in the histopathology report. 
 
20.0 AMENDMENTS AND DEVIATIONS 
 
Changes to the approved protocol will be made in the form of amendments which will be signed 
and dated by the Study Director with Sponsor approval.  Every reasonable effort will be made to 
discuss any necessary changes in advance with the Sponsor. 
 
Deviations from Good Laboratory Practices, the Study Protocol, Study Specific 
Procedures/Protocols and Standard Operating Procedures will be promptly reported to the Study 
Director and Sponsor to assess the impact on the quality and integrity of the study.  The 
deviations will be logged according to the appropriate Ribas lab SOP and documented on a 
deviation log sheet. The nature of the deviation, the effect on the study and the corrective action 
taken, if any, will be recorded in a Deviations log which will be included with the Final Report.  
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Module 3.2.P. Cell Product 
This section has been written following FDA guidelines for gene therapy as described in the 
Guidance for FDA Reviewers and Sponsors:  Content and Review of Chemistry, Manufacturing, 
and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications 
(INDs), April 2008. 
(A) PRODUCT MANUFACTURING-COMPONENTS AND MATERIALS 
1. VECTORS: Gene Therapy Vector Constructs
1.1 Retroviral Vector MSGV1-A2aB-1G4A-LY3H10 
The MSGV1-A2aB-1G4A-LY3H10 retroviral vector encodes for the NY-ESO-1 T cell receptor 
(TCR). Manufacturing information regarding this product can be found in IND 15167 (Sponsor: 
Ribas, UCLA), entitled “Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood 
Mononuclear Cells (PBMC) after a Nonmyeloablative Conditioning Regimen, with Administration 
of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients with Advanced 
Malignancies”. The Certificate of Analysis (CoA) for the MSGV1-A2aB-1G4A-LY3H10 retroviral 
vector can be found in Module 3.2.A, Appendix # 3.  
1.2 Lentiviral Vector LV-optNYESO TCR/sr39 TK 
1.2.1. Gene Therapy Vector Construct 
The immunotherapeutic lentiviral vector LV-optNYESO TCR/sr39TK will be used to transduce 
peripheral blood stem cells (PBSCs) allowing progeny cytotoxic T lymphocytes (CTLs) to 
specifically recognize NY-ESO-1-positive HLA-A2.1-positive tumor cells.  The integrated lentiviral 
vector LV-optNYESOTCR/TK consists of 9417 bps including the 3rd generation lentiviral self-
inactivating (SIN) long terminal repeats (LTRs), internal promoter from the murine stem cell virus 
(MSCV), packaging signal with the splicing donor and splicing acceptor sites, alpha chain and 
beta chain genes of the NY-ESO-1 TCR from Tumor Infiltrating Lymphocyte (TIL) clone 1G4 
α95:LY, and the positron emission tomography (PET) reporter/suicide gene sr39 thymidine kinase 
(TK). The alpha and beta TCR chains and the sr39TK genes are linked by 2A self-cleaving 
sequences (P2A and T2A, respectively). Figure 1 below shows a schematic of the integrated 
proviral part of this vector.  The plasmid pRRL-MSCV-opt NYESO-optsr39TK-WPRE-1 that was 
used to produce the LV-optNYESO TCR/sr39TK vector was generated in the Ribas laboratory at 
UCLA, and both were manufactured at clinical grade at the Indiana University Vector Production 
Facility (IUVPF).  Lentiviral stability studies were performed showing stability was not impacted 
within an 11 month period (Module 3.2.A, Appendix # 6). 
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The pRRL-MSCV-optNYESO optsr39TK-WPRE-1 is a self-inactivated 3rd generation lentiviral 
transfer vector containing chimeric Rous sarcoma virus (RSV)- 5′ LTRs. The vector contains a U3 
promoter region of MSCV that drives the expression of the TCR and a WPRE (woodchuck 
hepatitis virus posttranslational response element) sequence that enhances the expression of the 
transgene, vector stability and titer.  
 
The vector also contains the human immunodeficiency virus-1 (HIV-1) central polypurine tract 
(cPPT) that is important for nuclear import of the vector DNA and the Rev response element 
(RRE) that is essential for post-transcriptional transport of the unspliced and incompletely spliced 
viral mRNAs from the nucleus to the cytoplasm. The packaging signal directs the incorporation of 
the vector RNA into the virions. The LTRs of the vector contain the signals required for reverse 
transcription. The 3 proteins (TCR α chain, TCR β chain and sr39TK) are expressed through the 
same promoter fused with the self-cleaving 2A sequences. The TCR α and β chains are linked 
with a furin cleavage site (RAKR) followed by an SGSG spacer and P2A peptide (derived from 
porcine teschovirus-1) and the sr39TK is fused to the TCR β through a T2A (from Thoseaasigna 
virus).   
 
1.2.2 Vector Diagram.  
 
Please refer to Figure 1 below.  
 
Figure 1. LV-optNYESOTCR/TK lentiviral vector provirus. 
 
 
 
 
 
1.2.2   Sequence Analysis  
 
The vector sequence has been verified by transducing peripheral blood CD34+ cells with clinical 
grade LV-optNYESO TCR/sr39TK vector lot# 111015L12. The CD34+ cells were harvested 14 
days after transduction and DNA was extracted for sequencing. The sequence obtained was 
compared to the reference sequence obtained from the vector plasmid and no differences were 
seen. The full sequence of the vector and sequence analysis is reported in Module 3.2.A, 
Appendix # 2. 
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2. CELLS 
 
2.1 PBMC Transgenic for NY-ESO-1 TCR (RV-NYESO TCR PBMC) 
2.1.1  Cell Source 
The cell source is autologous PBMC from patients with advanced malignancies which will be 
collected by unmobilized leukapheresis at the UCLA Hemapheresis Unit. 
 
 
2.1.2  Collection or Recovery Method 
 
Patients will undergo an approximate 6-liter leukapheresis without prior mobilization to obtain 
PBMC for retroviral transduction. The leukapheresis product will be collected into sterile bags at the 
unit. The leukapheresis product will be transported to the cell-processing laboratory at the UCLA 
GMP facility. PBMC obtained from leukapheresis will be genetically modified with the clinical 
grade MSGV1-A2aB-1G4A-LY3H10 retroviral vector and infused fresh to patients after the lot 
release tests are completed.  
 
Additional manufacturing information about this product can be found in IND 15167 (Sponsor: 
Ribas, UCLA), entitled “Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood 
Mononuclear Cells (PBMC) after a Nonmyeloablative Conditioning Regimen, with Administration 
of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients with Advanced 
Malignancies” (also, see Module 5.3, Clinical Protocol, Section 10). 
 
2.1.3   Donor Screening and Testing 
 
Although these cells are for autologous use, as part of the screening process for inclusion into 
the study, subjects will be excluded from participation in the clinical trial if they have evidence of 
Human Immunodeficiency Virus (HIV), cytomegalovirus (CMV), Epstein-Barr Virus (EBV), 
Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Herpes Simplex Virus-1 (HSV-1).  
 
2.2 CD34+ PBSC Transgenic for NY-ESO-1 TCR/sr39TK (LV-NYESO TCR/sr39TK PBSC) 
 
2.2.1  Cell Source 
 
The cell source is autologous PBSC from patients with advanced malignancies, which will be 
collected by mobilized leukapheresis at the UCLA Hemapheresis Unit.  
 
2.2.2  Mobilization protocol 
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PBSC will be mobilized by administration of G-CSF and plerixafor.  Six months to 3 weeks prior 
to infusion of transduced cells, patients will undergo G-CSF and plerixafor mobilization of PBSC, 
which will be obtained by leukapheresis (Module 5.3, Clinical Protocol, Section 8.3). The 
mobilization protocol is summarized in Figure 2 below. 
 
 
 
 
 
 
 
Figure 2. Stem cell mobilization and manufacture scheme 
 
 
 
Patients will receive (or self-administer) G-CSF (10 µg/kg/day) subcutaneously on mobilization 
days (mDay) 1-4 in the morning.   
- On the evening of mDay 4, patients will begin receiving plerixafor (0.24 mg/kg/day 
subcutaneously).    
- Daily administration of G-CSF in the morning and plerixafor in the evening will continue until the 
target number of CD34+ cells and cells for backup are collected up to mDay 8.  A sufficient number 
of un-manipulated cells are required for backup in case of engraftment failure. 
 
2.2.3 Collection or recovery method 
 
G-CSF 10 µg/kg/day sc
Plerixafor 0.24 mg/kg/day sc
Mobilized Leukapheresis
mDay 8mDay 2 mDay 3 mDay 4 mDay 5 mDay 6 mDay 7mDay 1
Mobilization
Leukapheresisa
Leukapheresisb
mDay – Mobilization Day 
aCollection of unmodified stem cells for back up 
bCollection of stem cells for gene modification
Adapted from Micallef, et al.  Bone Marrow Transplantation.  2011, 46:350-355
≥ 3 Weeks
Lot Release Testing
Unmobilized
Leukapheresis
Day -5
TCR Tg PBSC Manufacture
mDay 6/7: CD34+ selection & transduction 
(Lentivirus  LV-optNYESOTCR/TK)
mDay 8/9:  Final Product Harvest & 
Cryopreservation
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- A 12-liter leukapheresis will begin approximately 10-11 hours after administration of plerixafor in 
the morning of mDay 5. Daily leukaphereses will continue until a sufficient number of cells for 
backup and transduction are collected up to mDay 8.  
- At least 2x106 CD34+ un-manipulated cells/kg (without CD34+ cell isolation) have to be obtained 
on mDay 5 and/or mDay 6 in order to proceed to collection of cells for transduction. Backup cells 
will be cryopreserved in liquid nitrogen vapors (≤ -140°C) in the UCLA Bone Marrow/Stem Cell 
Transplant Laboratory for possible future use if there is lack of engraftment (Figure 2) according 
to SOP 1023.02. 
- If enough cells are obtained for back up on mDay 5/6, mobilized cells will then be collected for 
transduction on mDay 6/7 through mDay 7/8 (depending on how many days it takes to collect 
backup cells) over a maximum of 2 days. 
- If a sufficient number of cells are obtained (≥2.5x106 nucleated cells/kg, after CD34 enrichment), 
CD34+ PBSC will be stimulated, transduced with the LV-optNYESOTCR/TK lentiviral vector and 
cryopreserved until ready for use after lot release testing. The number of transduced CD34+ cells 
needed is 2-6x106 cells/kg (Module 5.3, Clinical Protocol, Section 10).   
 
2.2.4 Donor screening and testing 
 
Although these cells are for autologous use, as part of the screening process for inclusion into 
the study, subjects will be excluded from participation in the clinical trial if they have evidence of 
Human Immunodeficiency Virus (HIV), cytomegalovirus (CMV), Epstein-Barr Virus (EBV), 
Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Herpes Simplex Virus-1 (HSV-1).  
 
3. REAGENTS 
3.1 Tabulation of Reagents Used in Manufacture 
 
Table 1. Reagents used in cell product manufacturing process 
 
RV-NYESO TCR PBMC##TCR PBMC## 
Reagent  Vendor/Supplier Final 
concentration 
Use Source Grade 
PBMC Isolation 
Ficoll-Paque 
PLUS GE Healthcare (×1) 
Density 
gradient N/A 
Research
* 
 
0.9% Sodium 
Chloride 
(normal saline) 
Baxter (×1) Buffered 
medium for 
PBMC 
collection  
 
N/A USP* 
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Cell culture and transduction 
AIM-V® Medium 
CTS TM  
Gentamicin 
Sulfate [-] 
Streptomycin 
Sulfate [-] 
Life Technologies 
Custom 
manufactured 
(×1) Culture Media  GMP* 
Human AB 
Serum 
Omega Scientific, 
Inc. 
5% in AIM-V Component in 
culture media 
Human Research
* 
IL-2 Boehringer 
Ingelheim 
300 IU/ml Component in 
culture media 
E. Coli USP* 
OKT-3 (anti- 
human CD3 
antibody) 
Miltenyi Biotec 50 ng/ml Component in 
stimulation 
media 
Mouse GMP* 
PBS Lonza (×1) Used to dilute 
Retronectin 
N/A Research
* 
HBSS Lonza (×1) Component in 
Retronectin 
washing 
buffer 
N/A Research
* 
Hepes Lonza (×1) Component in 
Retronectin 
washing 
buffer 
N/A Research
* 
Recombinant 
human 
fibronectin 
fragment 
(Retronectin)  
Takara/Clontech  
 
10μg/ml Facilitates 
lentiviral gene 
transduction  
 
N/A GMP* 
RV-NYESO-TCR 
vector 
IUVPF N/A  N/A GMP*★ 
Final  formulation 
0.9% Sodium 
Chloride 
(normal saline) 
Baxter (×1) Component 
of final 
formulation 
media  
N/A USP* 
Albumin 
(Human) U.S.P., 
25% 
Grifols 1% in normal 
saline 
Component 
of final 
formulation 
media 
Human USP* 
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LV-NYESO TCR/sr39TK PBSC 
Reagent  Vendor/Supplier Final 
concentration 
 
Use Source Grade 
CD34 isolation 
CliniMACS 
PBS/EDTA 
Buffer 
MACS Miltenyi 
Biotec 
(×1) 
Cell wash 
N/A Clinical* 
IVIG 
(Gammagard) 
  
Baxter 
International Inc. 
5% prior CD34 
selection 
Blocking prior to 
CD34 selection 
Human 
USP* 
CliniMACS® 
CD34 Reagent  Miltenyi Biotec 
7.5ml/6x10^6 
cells 
 
CD34 selection N/A Clinical*# 
Albumin 
(Human) 25% 
Grifols 0.5% in 
PBS/EDTA 
buffer 
Component of 
the washing 
PBS/EDTA 
buffer 
Human 
USP* 
Cell culture and transduction 
X-Vivo 15 Lonza (×1) 
Culture media 
N/A Research
* 
MACS GMP 
Recombinant 
Human SCF 
MACS Miltenyi 
Biotec 50 ng/ml 
Supports 
hematopoietic 
culture 
expansion  
 
E. Coli GMP* 
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MACS GMP 
Recombinant 
Flt3-Ligand 
MACS Miltenyi 
Biotec 
50/ng/ml Supports 
hematopoietic 
culture 
expansion  
 
E. Coli GMP* 
MACS GMP 
Recombinant 
Human TPO 
MACS Miltenyi 
Biotec 
50 ng/ml Supports 
hematopoietic 
culture 
expansion  
 
E. Coli GMP* 
MACS GMP 
Recombinant 
Human IL-3 
Miltenyi Biotec 20 ng/ml Supports 
hematopoietic 
culture 
expansion  
E. Coli GMP* 
Recombinant 
human 
fibronectin 
fragment 
(Retronectin)  
Takara/Clontech  
 
4μg/cm2 Facilitates 
lentiviral gene 
transduction  
 
N/A GMP* 
DPBS Life Technologies  (×1) Washing buffer N/A Research
* 
Hanks' BSS 
(HBSS) 
Lonza (×1) Washing buffer N/A Research
* 
Albumin 
(Human) 
U.S.P., 25% 
Grifols 0.5% in 
PBS/EDTA 
buffer 
Washing buffer 
1% in HBSS 
Blocking buffer 
2% in DPBS 
Human USP* 
Sterile Water 
for Injection 
Hospira 
Healthcare 
(×1) Cytokine and 
Retronectin 
reconstitution 
N/A USP* 
LV-optNYESO 
TCR/sr39TK 
IUVPF 50 MOI  Human GMP*# 
Cryopreservation and final formulation 
Pentastarch 
Solution 
Preservation 
Solutions 
(×1) Component of the 
cryopreservation 
media 
N/A USP* 
Plasma-Lyte  Baxter (×1) Component of 
cryopreservation 
media 
N/A USP* 
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Cryoserv Mylan 
Institutional 
5% in 
cryopreservati
on media 
Component of 
cryopreservation 
media 
N/A USP* 
Albumin 
(Human) 
U.S.P., 25% 
Grifols 5% in 
cryopreservati
on media 
Component of 
cryopreservation 
media 
Human USP* 
 
*Example Certificate of Analysis attached for each reagent (Module 3.2.A Appendix # 3) 
# Refer to corresponding cross-reference letter (Module 1.4, Appendix # 4) 
★ Refer to cross-reference letter as in IND 15167 (Module 1.4, Appendix # 2) 
## This is an updated list of the reagents for RV-NYESO TCR PBMC manufacturing; it has also been recently been 
updated in IND 15167, it includes updated vendors and reagent grades. 
 
3.2 Qualification Program 
 
Research-grade reagents used in manufacturing will be assessed based on the vendor’s 
Certificates of Analysis. If according to the manufacturer’s CoA, a reagent was not assessed for 
safety (sterility, endotoxin, mycoplasma, adventitious agent), we will test an aliquot for sterility 
(CLIA Certified Microbiology Laboratories) and endotoxin (EndoSafe®-PTSTM). Testing for 
mycoplasma and adventitious agents will not be performed unless warranted (i.e. production of 
the reagent involved cell culture or the preparation of the reagent involved animal products). This 
process will be repeated each time a new lot of reagent is used.  
 
3.3 Removal of reagents from final product 
 
After culture, the cells will be washed in a buffer consisting of HBSS + 1% HSA (LV-NYESO 
TCR/sr39TK PBSC) or normal saline (RV-NYESO TCR PBMC) for a minimum of three times 
before the final formulation.  
 
3.4 Other concerns 
 
Antibiotics are not used during the manufacture of the therapeutic product. 
 
3.5 Excipients 
 
The final product will be formulated in normal saline supplemented with 1%HSA (RV-NYESO TCR 
PBMC) or in a cryopreservation solution consisting of Plasmalyte-A and DMSO (Cryoserv) (5%), 
Pentastarch (6%), HSA (5%).  
 
(B) PRODUCT MANUFACTURING-PROCEDURES 
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1. VECTOR PRODUCTION/PURIFICATION 
1.1. Retroviral vector RV-NYESO TCR 
The vector was manufactured at IUVPF following FDA Good Manufacturing Practice 
(GMP) guidelines. Please refer to IUVPF’s letter authorizing cross-reference to BB MF 
8653  (Module 1.4, Appendix # 2) issued for IND 15167, entitled “Adoptive Transfer of NY-
ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) after a 
Nonmyeloablative Conditioning Regimen, with Administration of NY-ESO-1157-165 Pulsed 
Dendritic Cells and Interleukin-2, in Patients with Advanced Malignancies”. 
 
1.2. Lentiviral Vector (LV-NYESO TCR/sr39TK)  
 
The vector was produced at IUVPF following FDA GMP guidelines.  Please see authorization 
letter from IUVPF to cross-reference BB MF 10640 (Module 1.4, Appendix # 3).  
 
2. PREPARATION OF EX VIVO GENE-MODIFIED AUTOLOGOUS CELLS 
2.1. RV-NYESO TCR PBMC  
 
PBMC obtained from leukapheresis will be activated for 48 hours with OKT3 (anti-CD3 antibody) 
and IL-2 and then genetically modified with the clinical grade MSGV1-A2aB-1G4A-LY3H10 
retroviral vector supernatant for two consecutive days. These cells will be maintained in culture 
for 4 days from the start of transduction in media supplemented with IL-2 and then are infused 
fresh to patients. Aliquots of these cells will be used to fulfill the lot release criteria.  
 
Additional manufacturing information about this product can be found in IND 15167 (Sponsor 
Ribas, UCLA), entitled “Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood 
Mononuclear Cells (PBMC) after a Nonmyeloablative Conditioning Regimen, with Administration 
of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients with Advanced 
Malignancies” (also, see Module 5.3, Clinical Protocol, Section 10).  
 
2.2  LV-NYESO TCR/sr39TK PBSC  
2.2.1  Cell Collection/Processing/Culture 
The overview of the manufacturing procedure is summarized in Figure 3 below. 
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Figure 3. Product manufacturing scheme 
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Cells will be collected from the subject’s mobilized peripheral blood by leukapheresis at the UCLA 
Hemapheresis Unit and transported to the cell-processing laboratory at the UCLA GMP facility. A 
sample will be submitted for CBC and CD34+ cell enumeration (ISCHAGE flow cytometric method). 
The initial fresh leukapheresis product will be washed to decrease platelet content. The CD34+ cell 
population will be enriched using CliniMACS®CD34 reagent system, which consists of CliniMACS® 
Plus Instrument, CliniMACS® single use, sterile, disposable tubing set and CliniMACS® PBS/EDTA 
buffer following a standard manufacturing procedure (SOP) developed based on the manufacturer's 
instructions. The resulting cell fraction will be characterized for total cell number, viability, and 
percentage of CD34+ cells.  
 
2.2.2  Acceptance criteria 
- If the resulting CD34+ cell number is ≥2.5 x106 nucleated cells/kg, after CD34 enrichment, the cells 
will be processed for gene modification. If the resulting nucleated cell number is <2.5 x106 cells/kg 
the subject will be withdrawn from further study participation. 
- If sufficient CD34+ cells are obtained from the CliniMACS® and the procedure continues, additional 
testing on the CD34+ fraction will include a CFU assay in methylcellulose and sterility. 
2.2.3  Pre-stimulation (Day 0 i.e. mDay 6/7 – see Figure 2) 
The cells will be cultured at a concentration of 1x106 cells/ml on Retronectin coated surfaces and 
pre-stimulated for 18 ± 6 hours (~37° C, 5% CO2) in serum-free X-VIVO15 medium supplemented 
with the following cocktail of cytokines: rhSCF (50ng/ml), Flt-3 ligand (50ng/ml), TPO (50 ng/ml) and 
IL-3 20ng/ml.  An in-process sterility sample will be collected and submitted for analysis. 
2.2.4  Transduction (Day 1 i.e. mDay 7/8 – see Figure 2) 
After the pre-stimulation period, non-adherent cells will be removed from the culture flasks and spun 
down in sterile 250ml centrifuge tubes.  An aliquot of supernatant will be sampled and submitted for 
sterility testing.  The non-adherent cells will be resuspended in fresh cytokine-containing medium.  
The resuspended non-adherent cells will be added back to the original flasks containing the adherent 
cell fraction at an approximate cell density of 2-3 x106 cells/ml.  The LV-NYESO sr39TK vector will 
be added at a final multiplicity of infection (MOI) of 50 (50 TU/cell) performed in two rounds of 
transduction of 25 MOI each. The total transduction period is 18 ± 6 hours (~37° C, 5% CO2). In-
process test results prior to final product harvest are summarized in Table 2. 
 
   Table 2. Summary of In-Process Test Results 
 
Sample description Test 
Description 
Method Specification for 
Intermediate 
Acceptance 
Mobilized 
Leukapheresis 
CD34+ 
enumeration 
ISHAGE ≥2×106 cells/kg 
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 CBC Automated cell 
counter 
Report results 
Post-CliniMACS 
Positive fraction 
CD34+ 
enumeration 
ISHAGE ≥2.5×106 nucleated 
cells/kg  
CFU potential Methylcellulose 
culture 
Report results 
VCN ddPCR Report results 
Sterility culture  Negative  at the day of 
cryopreservation 
18±Post stimulation Sterility culture  Negative  at the day of 
cryopreservation 
18±Post transduction CD34+ 
enumeration 
ISHAGE ≥2×106 cells/kg  
RCL supernatant  Banked 
 
2.2.5  Cell product harvest (Day 2 i.e. mDay 8/9) 
 
 After 36 ± 12 hours from the initiation of culture, the entire cell culture (consisting of adherent and 
non-adherent cells) will be harvested for formulation and infusion. The adherent cells will be 
collected by washing with HBSS/1%HSA.  The adherent and non-adherent cell suspensions will 
be centrifuged.  Following centrifugation, a portion of the supernatant from each tube will be 
removed, pooled together and banked (frozen) for replication competent lentivirus (RCL) testing. 
RCL testing will be performed only if warranted (i.e. RCL is detected in the subject’s peripheral 
blood during the follow-up period).   
 
2.2.6  Cell product formulation 
The cells will be washed 3 times in wash buffer (HBSS + 1% HSA) and then resuspended and 
formulated in cryopreservation solution consisting of Plasmalyte-A/DMSO (Cryoserv) 
(5%)/Pentastarch (6%)/HSA (5% at a concentration of 1.5-40×106 cells/ml). All the reagents used 
for final formulation are clinical grade. The formulated cell suspension will be filled into cryobags. 
The final formulation volume will acount for the QC tests, RCL (1% of the final product) and 
reserve sample/s that will be collected from the cell product container immediately following the 
fill and cryopreserved separately in sterile cryovials. Cell product, RCL, reserved and  QC samples 
will be cryopreserved using a controlled-rate freezer at the same time under the same conditions. 
Upon completion of the controlled freeze, the cell product cryobags and QC samples will be 
transferred to storage in the vapor phase of LN2.  Cryobags with cell product will be stored in the 
vapor phase of LN2 until released and required for administration into the subject. The 
cryopreserved QC sample will be thawed and subjected to lot release testing as summerized in 
Table 3. 
 
Table 3: Final lot release criteria  
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Test  Method Acceptance Criteria Performed 
at 
CD34 enumeration 
 
ISHAGE 
flow cytometric method 
≥2.5×106 nucleated 
cells/kg, after CD34 
enrichment 
 
CTL 
 
% CD34 purity ISHAGE 
flow cytometric method 
 
≥50% CTL 
 
Cell viability  Trypan Blue manual count ≥70% In House 
Vector copy number ddPCR 0.1-2 copies/cell In House 
Sterility Sterility culture Negative CTL 
Fungal culture Negative  CTL 
Endotoxin Endosafe®PTS ≤ 5 EU/Kg In House 
Mycoplasma MycoAlert test Ratio<1 In House 
CFU assay CFU potential 
Methylcellulose 
≥10% In House 
% LV-NYESO+ 
CFUs 
ddPCR 5%-50% LV-NYESO+ 
colonies*  
In House 
Vβ13.1# expression Flow Cytometry 5%-50% of Vb13.1+ cells* In House 
CTL- Contract Testing Laboratory 
#Vb13.1 is TCR β chain variant of NY-ESO-1 TCR 
* In order to make sure that the repertoire of endogenous TCRs will not be compromised, at least 50% of the 
CD34+ PBSC delivered to the patient will be untransduced. 
 
The cryopreserved gene-modified cells will be thawed and infused only after the product 
manufacturing batch record has been reviewed and the product has been released by quality 
assurance personnel. The number of the infused cells will be limited to ≤ 6 x 106 cells/kg.  If the 
number of cells harvested after culture exceeds this limit, the remaining cells will be discarded or 
released for research.  
 
Stability studies of the cryopreserved final cell product have been conducted. Preliminary stability 
results show that the cell product stored in the vapor phase of LN2 is stable for up to 6 months 
post-cryopreservation and for up to 24 h at 4-8°C post-thaw, the results have been included in 
the final cell product stability report. 
 
2.2.7  Administration of Cryopreserved Cell Product into the Subject 
   
Cells will only be administered to patients at a single site at UCLA.  The cells will not be shipped.  
For transport within the UCLA clinical site, cell product cryobag(s) will be placed into a 
temperature monitored dry nitrogen shipping container.  For administration, the shipping container 
will be taken directly to the subject’s bedside.  Immediately prior to infusion,  cell product 
cryobag(s) will be removed from the shipping container and thawed using either a plasma thawing 
device or a pre-warmed water bath. Upon thaw, cell product bag(s) will immediately be infused 
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directly without further manipulation per  Bone Marrow/Stem Cell Transplantation Unit’s  infusion 
SOP. 
 
(C) OTHER 
1. PRODUCT TRACKING  
The product tracking will be performed per SOP # C1040, Product Tracking. In most cases, only 
one cell product will be manufactured at a time. In the event that more than one product is 
manufactured in a clean room, the surfaces and equipment will be thoroughly cleaned, all opened 
reagents and trash removed between procedures as part of the change control procedure as per 
GMP facility SOP# 420-Change Control Procedure.  
2. PRODUCT LABELING 
The product labeling will be performed per SOP# 1050, Cell product and related sample labeling. 
The examples of the labels  for RV-NYESO TCR PBMC and LV-NYESO TCR/sr39TK PBSC cell 
products are shown in Figure 4. 
 
FIGURE 4: Example of the label for LV-NYESO TCR/sr39TK PBSC cell product 
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 Figure 4 Continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. CONTAINER/CLOSURE 
The final product container is a CryoStoreTM CS50 Cryobag (OriGen biomedical) which is a Class 
I 510(k) cleared medical device (pre-market submission number BK030036).  
 
4. ENVIRONMENTAL IMPACT 
We request a categorical exclusion from the requirements of preparing an environmental 
assessment. The drugs described in this IND are intended to be used for clinical studies and/or 
research programs in which waste disposal will be controlled, the amount of waste expected to 
enter the environment is reasonably expected to be nontoxic and in minimal quantities, and to the 
knowledge of the applicant, no extraordinary circumstances exist (21 CFR 25.15 (d)). 
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5. QUALIFICATION OF THE MANUFACTURING PROCESS  
The autologous mobilized peripheral blood harvest and CD34+ isolation procedures will be 
performed per established SOPs. 
 
The UCLA QC plan and a description of the UCLA GMP Manufacturing Suite is attached in 
Module 3.2.A, Appendix # 5.  Specifically, the following functions are addressed: 
 
• Examination of components used in the manufacturing process GMP facility SOP 1100,     
Receipt of Reagents & Supplies. 
• Releasing or rejecting a clinical batch GMP facility SOP 1010, Product Release. 
•  Investigating and Initiating corrective action GMP facility SOP 440, Reporting deviations and 
GMP facility SOP 441, Corrective and Preventive Action Plans. 
• Review and Approval of production procedures, testing procedures and acceptance criteria 
GMP facility SOP 490, Document control. 
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1. BACKGROUND  
 
The stability of LV-NYESO TCR/sr39TK PBSC (also referred to as cell product) post-
cryopreservation has been determined using the cryopreserved cell products from five healthy 
donors that were manufactured independently. The stability validation procedure was performed 
following SOP # 1610: Stability assessment of the cryopreserved LV-NYESO TCR sr39TK 
transduced autologous PBSC. The study was conducted per protocol AR-CIRM-17-002-P. As 
detailed herein, all acceptance criteria were either directly met, or any protocol discrepancies 
identified were investigated, justified and determined to have no impact on the qualification. 
2. PURPOSE 
 
To compare the attributes and stability of Peripheral Blood Stem Cells (PBSC) transduced 
with LV-NYESO TCR/sr39TK as a fresh formulation and cryopreserved in Cryoserv/Pentastarch 
cryopreservation media.  
3. SCOPE  
The current study compared the attributes of the fresh cell product with the cryopreserved cell 
product formulated in Cryoserv/Pentastarch cryopreservation media and assessed:  
3.1. The long term stability of the cryopreserved cell product after 30 ±7 days (1 month), 90±7 
days (3 months), 180±10 days (6 months) and 360±14 days (1 year) at ≤ -140°C (vapor 
phase of liquid nitrogen (LN2).  
3.2. The short-term stability of the thawed cell product after 3, 6, 24 and 48 hours at ambient 
temperature and 4-8°C.  
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4. RESPONSIBILITY 
 
Sponsor: Antoni Ribas, MD, PhD University of California, Los Angeles 
Test Facility: Ribas Lab 14-638 Factor Bldg. UCLA Medical Center 10833 Le Conte Ave Los Angeles, CA 90095 
Principal 
Investigator:  
Antoni Ribas , MD, PhD University of California, Los Angeles 
Study Coordinator: Beata Berent-Maoz, PhD University of California, Los Angeles 
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5. ACCEPTANCE CRITERIA 
 
 
* Analyses performed after cells are cultured for 14 days to avoid over estimating vector copy 
number (VCN) and potency due to the presence of un-integrated forms of the lentiviral vector. 
# The endotoxin level was calculated based on the weight of the donor reported by a vendor.   
Test Method 
Specification 
Fresh cell 
product 
Specification 
Thawed cell 
product 
CD34+ cell enumeration (cells/ml) 
 
Flow Cytometry 
(ISHAGE Protocol)  
Record results Record results 
% CD34+ cells (purity) Flow Cytometry 
(ISHAGE Protocol) 
≥50% ≥50% 
%TNC viability  Trypan Blue manual 
count 
≥70% ≥70% 
% CD34+ cell recovery  Record results Record results 
Endotoxin# Endosafe®PTS ≤ 5 EU/Kg  ≤ 5 EU/Kg  
Mycoplasma MycoAlert test Ratio<0.9 Ratio<0.9 
Sterility Sterility culture No growth No growth 
Fungal culture No growth No growth 
%Vβ13.1 positive cells Flow Cytometry Record results Record results 
CFU potential Methylcellulose culture 
(%CFU/cells plated) 
Record results Record results 
% LV-NYESO TCR/sr39TK positive 
CFU 
ddPCR Record results Record results 
Vector copy number (VCN)* ddPCR and/or qPCR Record results Record results 
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6. REFERENCES AND APPLICABLE DOCUMENTS 
 
SOP# C1610 - Stability assessment of the cryopreserved LV-NY-ESO1 TCR sr39TK transduced 
autologous CD34+cells. 
SOP # C1000- Transduction of CD34+ cells with LV-NY-ESO 1 TCR sr39/TK. 
SOP# C1601- CD34+ cell separation – CliniMACS Plus (One Leukapheresis Product) 
7. HEALTH AND SAFETY CONSIDERATIONS 
 
Refer to the Health and Safety Considerations section of the specific production batch records 
(PBRs), standard operating procedures (SOPs) and applicable manuals employed in this protocol, 
including those for the handling of compressed gases and LN2. 
8. DEFINITIONS  
8.1. °C: Degree Centigrade 
8.2. CFU: Colony Forming Unit 
8.3. CO2: Carbon Dioxide 
8.4. CRF: Controlled Rate Freezer 
8.5. ddPCR: Droplet Digital Polymerase Chain Reaction 
8.6. FCP: Fresh Cell Product 
8.7. HD: Healthy Donor 
8.8. HSC: Hematopoietic Stem Cell 
8.9. LN2: Liquid Nitrogen 
8.10. LV: Lentivirus 
8.11. MBR: Manufacturing Batch Record 
8.12. MOI: Multiplicity of Infection 
8.13. PB: Peripheral Blood 
8.14. PBSC: Peripheral Blood Stem Cells 
8.15. qPCR: quantitative Polymerase Chain Reaction 
8.16. SOP: Standard Operating Procedure 
8.17. TCP: Thawed Cell Product 
8.18. TE: Transduction Efficiency 
Stability evaluation of PBSC transduced with LV-optNYESO 
TCR/sr39TK     
Report  AR-CIRM-17-002-R Version: 01 Effective Date:_______________ Page 7 of 28   
8.19. TNC: Total Nucleated Cells 
8.20. TU: Transduction Unit 
8.21. VCN: Vector Copy Number 
9. EQUIPMENT AND MATERIALS 
 
9.1. Equipment, Reagents and Consumables 
Refer to the SOP# C1610, for a comprehensive list of equipment, reagents and 
consumables. 
9.2. Starting materials 
9.2.1. LV-NYESO TCR/sr39TK  
The pRRL-MSCV-optNYESO-optsr39TK-WPRE construct was developed in the 
research laboratory of Dr. Antoni  Ribas at UCLA. The lentiviral vector was 
generated at the Indiana University Vector Production Facility (IUVPF; lot# 
071013BSL12 for GMP comparable vector, CoA issued Sep 04, 2013; or lot# 
111015L12 for clinical grade vector, CoA issued Sep9, 2016).  The titers of the 
GMP comparable and clinical vector are 6.7 x10e8 and 2.0x10e8 Transducing 
Units (TU)/mL, respectively. The LV-NYESO TCR/sr39tk vector will be used to 
transfer a functional copy of the genes encoding NY-ESO-1 TCR and HSV1-
sr39TK to CD34+ cells isolated from mobilized peripheral blood. 
9.2.2. Human CD34+ cells 
The cell product was manufactured from human CD34+ cells isolated from 
mobilized peripheral blood following the laboratory's SOPs.   
9.2.3. Source of human cells 
G-CSF mobilized peripheral blood from healthy donors.   
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10. PROCEDURES 
 
10.1. Number of manufacturing runs 
Five independent manufacturing runs from 5 healthy donors (HD1-HD5) were carried out 
and the stability of cell products made from these runs was assessed in this study. 
  
10.2. LV-NYESO TCR/sr39TK PBSC cryopreservation 
LV-NYESO TCR/sr39TK PBSC were manufactured from human CD34+ cells isolated from 
mobilized peripheral blood following the laboratory's SOP-C1601, and transduced 
following SOP # C1000. The LV-NYESO TCR/sr39TK PBSC product was harvested and 
formulated in cryopreservation solution consisting of Plasmalyte-A; (5%) DMSO 
(Cryoserv); (6%)/Pentastarch and (5%) (SOP# C1000). Aliquots of fresh cell product 
samples were collected for further product characterization. Cell product was divided into a 
number of cryopreservation bags based on cell availability and cryopreserved using a 
controlled-rate freezer and transferred to LN2 (≤-140°C) freezer (SOP C1000). The final 
volume of cell product was either 10 or 20 ml. The cell concentration in the cell product 
varied based on cell availability. 
10.3. TCR/sr39TK PBSC stability evaluation 
Stability of the cell product was evaluated following SOP# C1610 “Stability assessment of 
the cryopreserved LV-NY-ESO1 TCR sr39TK transduced autologous CD34+cells”. 
10.3.1. The long-term stability of the frozen cell product was evaluated after storage in the 
vapor phase of LN2 (≤-140°C) for 30±7 days (1 month), 90±7 days (3 months), 
180±10 days (6 months). The time point of 360±14 days (1 year) has not been 
evaluated as of the time of this report but will be evaluated in the future and the 
report will be amended to include this data. In the last two runs, (HD4 and HD5), the 
cell product thawed shortly (1-3 days) after cryopreservation (TCP day 0) was 
assessed as well.  The number of time points evaluated from each cell product was 
dependent on the number of cells available. The Table 1 below summarizes the time 
points evaluated from each run. Cell product was thawed at 37°C and samples were 
taken to determine the quality attributes of the thawed cell product and to compare 
to those of the fresh cell product.   
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Table 1: Long term stability time points evaluated in donors HD1-HD5. 
 FCP TCP 
 Day 0 
TCP 
 Day 30 
TCP  
Day 90 
TCP 
 Day 180 
HD1 ✔  ✔ ✔ ✔ 
HD2 ✔  ✔ ✔  
HD3 ✔  ✔  ✔ 
HD4 ✔ ✔ ✔   
HD5  ✔ ✔   
 
10.3.2. To evaluate the post-thaw stability over a 48-hour period, the thawed cell product 
was split into two cryo-bags.  One bag was stored at ambient room temperature and 
the other was refrigerated in a temperature-monitored refrigerator. At each of the 3, 
6, 24 and 48-hour time points, 1.5-3 mL samples were taken from each of the bags 
and evaluated for TNC numbers, viability, CD34+ cell numbers and CFU potential.  
10.4. Quality assessment tests 
Quality parameters were asessed as follows:  
10.4.1. Sterility was assessed by bacterial and fungal cultures for 14 and 21 days, 
respectively. The samples were submitted following SOP# 2100-Sample submission 
to clinical microbiology lab. 
10.4.2. Endotoxin levels  were assessed by using the Endosafe®-PTSTM test system which 
utilizes the LAL kinetic chromogenic methodology. The system consists of a  
spectrophotometer and FDA-licenced Endosafe®-PTSTM test cartridges that contain 
the precise amount of LAL reagent, chromogenic substrate and control standard 
endotoxin (CSE). The test  system measures a color intensity that is directly related 
to the endotoxin concentration in a sample. The test was done following SOP# 2400 
- Endotoxin Assay using Endosafe PTS.  
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10.4.3. Mycoplasma  levels were assessed by using the MycoAlert™ Mycoplasma 
Detection Kit, a biochemical test that exploits the activity of mycoplasmal enzymes. 
The test was done following SOP# 2500- Mycoplasma Assay using MycoAlertTM. 
10.4.4. Total nucleated cell viability was asessed by trypan blue exlusion assay (SOP 
C1610 - LV-NY-ESO1 TCR sr39TK Autologous CD34+ stability asessment). 
10.4.5. CD34+ cell recovery was calculated by dividing the “post-cryopreservation CD34+ 
cells/ml” by “fresh CD34 cells/ml” for long term stability study or by “0h CD34 cells/ml” 
for 3, 6, 24 and 48 h post-thaw time points and multiplying by 100%.  
10.4.6. CD34+ cell enumeration was performed using the single-platform ISHAGE flow 
cytometric method following the testing facility SOP. 
10.4.7. CFU potential  was assessed by culturing CD34+ cells in a methylcellulose based 
medium for 13-15 days followed by colony enumeration and characterization based 
on  their unique morphology. The assay was performed following SOP# C1800- 
Colony Forming Unit (CFU) Assay In Methylcellulose for human CD34+ cells.  
10.4.8. Transduction efficiency 
10.4.8.1. The vector copy number (VCN) of integrated lentivirus per cell of  the 
bulk cell culture was assessed by plating 5×104 cells in media promoting 
myeloid differentiation and culturing for 14 days. The cells were 
harvested and genomic DNA was isolated  (SOP# C1300-Total DNA 
extraction for VCN analysis) to  determine average vector copy number 
(VCN) per cell by droplet digital PCR (ddPCR) (SOP# C1200-VCN 
quantification by ddPCR).The average VCN in the cell product was 
determined by normalizing the HIV-1 packaging signal sequence (Psi) to 
the cellular autosomal gene syndecan 4 (SDC4) as described in Cooper 
et al. J Viral Methods, 2011. 
10.4.8.2. The Percentage of  LV-NYESO positive  CFUs was assessed following  
the CFU enumeration procedure.  Single CFUs were individually picked 
for genomic DNA isolation (SOP# C1500-Genomic DNA extraction from 
Colony Forming Units) and determination of VCN/cell by ddPCR (SOP# 
C1200-VCN quantification by ddPCR).   
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10.4.8.3. Intracellular Vbeta 13.1 chain expression (TCR β chain variant specific 
for NY-ESO-1 TCR) was assessed by flow cytometry per SOP # C1900-
Evaluation of the transgene TCRVbeta13.1 expression on transduced 
Stem Cells.  
11.  STATISTICAL ANALYSIS  
Parameters regarding the manufacturing and in vitro characterization of the final cell products 
were tabulated and reported for each donor. Descriptive statistics such as mean and standard 
deviation were calculated. Linear mixed modeling approach was adopted to evaluate the long-
term (Tables 6-8, Figure 1) stability and short-term stability (Figure 3) of the cryopreserved cell 
products. Specifically, donor-to-donor variations were modeled through random intercepts, while 
time was treated as a fixed effect. Within the linear mixed model framework, an overall test of time 
effect was performed, followed by Tukey-Kramer adjusted pairwise comparisons. All statistical 
tests for significance were two-tailed. A p-value less than the 0.05 significance level was 
considered to be statistically significant. All statistical analyses were carried out using SAS 
version 9.4 (SAS Institute Inc. 2013). 
 
12. RESULTS  
12.1. Long-term stability of the cryopreserved cell product after 30, 90 and 180 days post 
cryopreservation. 
To determine the stability of the cell product during cryopreservation, five independent  
LV-NYESO TCR/sr39TK PBSC cell products were manufactured and underwent stability 
assessment. The time points at which stability was assessed were based on cell 
availability.  
The results for the recovery of cell product of the individual donors are summarized in 
Tables 1-5. The parameters that didn’t meet the acceptance criteria as defined in protocol 
AR-CIRM-17-002-P are indicated in each of the tables.  
 
Table 6 summarizes the parameters that reflect cell product stability i.e. viability, CD34 
recovery and clonogenic potential before and after 30, 90 and 180 days following 
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cryopreservation of the cell product. The data indicates that the cryopreservation didn’t 
affect any of these parameters at the time points tested.  
The cryopreservation also did not affect the distribution of erythroid (BFU-E/CFU-E), 
myeloid (CFU-G/M/GM) and multi-lineage (CFU-GEMM) colonies (p values are 0.35, 0.66 
and 0.46 respectively)(Figure 1). The transduction level of the recovered cell product was 
not significantly changed during the storage in vapor phase LN, as measured by Vb13.1, 
average VCN and % of LV-NYESO TCR/sr39TK positive CFUs (Table 7 and Figure 2).   
In addition no significant difference was observed in parameters defining cell product 
purity i.e. endotoxin, mycoplasma sterility and percentage of CD34+ cells (Table 8). 
 
  
Stability evaluation of PBSC transduced with LV-optNYESO 
TCR/sr39TK     
Report  AR-CIRM-17-002-R Version: 01 Effective Date:_______________ Page 13 of 28   
 
 
Table 1: HD1-Comparison between fresh and cryopreserved product at 30, 90 and 180 days. 
  
Test Method Specifications FCP 
TCP 
30d 
TCP 
90d 
TCP 
180d 
CD34+ cell 
enumeration 
(cells/ml)  
Flow Cytometry 
(ISHAGE)  
Record results 3.0×106 2.7×106 2.8×106 2.5×106 
% CD34 cells (purity) Flow Cytometry 
(ISHAGE)  
≥50% 98.66 97.46 98.93 97.16 
%TNC viability  Trypan Blue manual 
count 
≥70% 99.5 98.5 98.1 98.0 
% CD34+ cell 
recovery 
 Record results 100 90.0 93.3 83.3 
Endotoxin  Endosafe®PTS ≤ 5 EU/Kg  0.095 0.058 0.072 0.058 
Mycoplasma MycoAlert test Ratio<0.9 0.18 0.50 0.53 0.22 
Sterility Sterility culture No growth No 
growth 
No 
growth 
No 
growth 
No 
growth 
Fungal culture No growth No 
growth 
No 
growth 
No 
growth 
No 
growth 
%Vβ13.1 positive 
cells 
Flow Cytometry Record results 18.8 16 20.3 9.85 
CFU potential Methylcellulose culture 
(%CFU/cells plated) 
Record results 51±14 58±2 53±13 51±11 
% LV-NYESO 
TCR/sr39TK positive 
CFU 
ddPCR Record results 35.4 44 24.5 26 
Vector copy number 
(VCN) 
ddPCR and/or qPCR Record results 0.1 0.1 0.3 0.1 
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Table 2: HD2-Comparison between fresh and cryopreserved product at 30 and 90 days. 
Test Method Specifications FCP 
TCP 
30d 
TCP 
90d 
CD34+ cell 
enumeration (cells/ml)  
Flow Cytometry 
(ISHAGE)  
Record results 1.4×106 1.1×106 1.2×106 
% CD34 cells (purity) Flow Cytometry 
(ISHAGE)  
≥50% 93.14 96.78 94.09 
%TNC viability  Trypan Blue 
manual count 
≥70% 97.2 98.2 96.0 
% CD34 recovery  Record results 100 78.6 85.7 
Endotoxin  Endosafe®PTS ≤ 5 EU/Kg  0.132 0.132 0.132 
Mycoplasma MycoAlert test Ratio<0.9 0.4 0.2 0.2 
Sterility Sterility culture No growth No growth No growth No growth 
Fungal culture No growth No growth No growth No growth 
%Vβ13.1 positive cells Flow Cytometry Record results 13.2% 3.7%# 18.6 
CFU potential Methylcellulose 
culture 
(%CFU/cells 
plated) 
Record results 64±4 44±6 42±5 
% LV-NYESO 
TCR/sr39TK positive 
CFU 
ddPCR Record results 21.4 29.6 16.5 
Vector copy number 
(VCN) 
ddPCR and/or 
qPCR 
Record results 0.1 0.3 0.1 
# Vb13.1 expression level for this time point iis lower than the other time points for this cell product. 
This value was incorporated in the average Vb13.1 percentage calculations (see table 7).   
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Table 3: HD3-Comparison between fresh and cryopreserved product at 30 and 180 days. 
Test Method Specifications FCP 
TCP 
30d 
TCP 
180d 
CD34+ cell enumeration 
(cells/ml)  
Flow Cytometry 
(ISHAGE Protocol)  
Record results 2.5×106 2.1×106 2.8×106 
% CD34 cells (purity) Flow Cytometry 
(ISHAGE Protocol) 
≥50% 97.68 88.75 97.84 
%TNC viability  Trypan Blue manual 
count 
≥70% 98.6 98.9 97.4 
% CD34 recovery  Record results 100 84.0 112.0 
Endotoxin  Endosafe®PTS ≤ 5 EU/Kg  0.139 0.139 0.139 
Mycoplasma MycoAlert test Ratio<0.9 0.46 0.31 0.34 
Sterility Sterility culture No growth No 
growth 
No 
growth 
No 
growth 
Fungal culture No growth No 
growth 
No 
growth 
No 
growth 
%Vβ13.1 positive cells Flow Cytometry Record results 24.9% 18% 9.18% 
CFU potential Methylcellulose culture 
(%CFU/cells plated) 
Record results 52±10 47±11 46±3 
% LV-NYESO TCR/sr39TK 
positive CFU 
ddPCR Record results 28.7 19 25.8 
Vector copy number (VCN) ddPCR and/or qPCR Record results 0.3 0.3 0.3 
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Table 4: HD4-Comparison between fresh and cryopreserved product at 0 and 30 days. 
Test Method Specifications FCP 
TCP 
0d 
TCP 
30d 
CD34+ cell 
enumeration 
(cells/ml)  
Flow Cytometry 
(ISHAGE)  
Record results 1.5×106 1.1×106 1.5×106 
% CD34 cells (purity) Flow Cytometry 
(ISHAGE)  
≥50% 94.14 95.5 97.04 
%TNC viability  Trypan Blue manual 
count 
≥70% 88.8 91.0 86 
% CD34 recovery  Record results 100 73% 100% 
Endotoxin  Endosafe®PTS ≤ 5 EU/Kg  0.129 0.181 0.097 
Mycoplasma MycoAlert test Ratio<0.9 0.23 0.21 0.23 
Sterility Sterility culture No growth No growth No growth No growth 
Fungal culture No growth No growth No growth No growth 
%Vβ13.1 positive 
cells 
Flow Cytometry Record results 30.9 32.5 37.2 
CFU potential Methylcellulose 
culture 
(%CFU/cells plated) 
Record results 36±1 33±6 36±6 
% LV-NYESO 
TCR/sr39TK positive 
CFU 
ddPCR Record results 31.4 43 30 
Vector copy number 
(VCN) 
ddPCR and/or 
qPCR 
Record results 0.4 0.4 0.4 
 
  
Stability evaluation of PBSC transduced with LV-optNYESO 
TCR/sr39TK     
Report  AR-CIRM-17-002-R Version: 01 Effective Date:_______________ Page 17 of 28   
Table 5: HD5-Comparison between cryopreserved cell product at day 0 and 30 days. 
Test Method Specifications 
TCP 
0d 
TCP 
30d 
CD34+ cell 
enumeration 
(cells/ml)  
Flow Cytometry 
(ISHAGE)  
Record results 1.4×106 1.5×106 
% CD34 cells 
(purity) 
Flow Cytometry 
(ISHAGE) 
≥50% 96.27 97.95 
%TNC viability  Trypan Blue manual 
count 
≥70% 96.2 95.2 
% CD34 recovery#  Record results 93.3% 100% 
Endotoxin#  Endosafe®PTS ≤ 5 EU/Kg  0.101 0.155 
Mycoplasma MycoAlert test Ratio<0.9 0.07 0.39 
Sterility Sterility culture No growth No growth No growth 
Fungal culture No growth No growth No growth 
%Vβ13.1 positive 
cells 
Flow Cytometry Record results 31.4% 35.3% 
CFU potential Methylcellulose culture 
(%CFU/cells plated) 
Record results 46±10 39±4 
% LV-NYESO 
TCR/sr39TK 
positive CFU 
ddPCR Record results 37% 36% 
Vector copy 
number (VCN)* 
ddPCR and/or qPCR Record results 0.4 0.5 
# For this run %CD34 recovery is calculated based on cell concentration of CD34+ cells prior to 
cryopreservation (1.5×106 cells/ml).   
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Table 6: Long term stability parameters  
Tests 
FCP 
N=4 
TCP 
0 days 
N=2 
TCP 
30days 
N=5 
TCP 
90 days 
N=2 
TCP 
180 Days 
N=2 
P 
value 
TNC viability 
(%) 
96.03±4.9 93.6±3.4 95.4±5.4 97.1±1.5 97.7±0.4 0.17 
CD34 
recovery (%) 
100 83.15±14.35 90.52±9.55 89.50±5.37 97.65±20.29 0.31 
CFU potential 
(%) 
51±11 40±9 45±9 48±8 49±4 0.67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The percentages of the different types of hematopoietic colonies identified are 
presented. Data is presented as mean±SD and grouped by sample type. 
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Figure 2. Transduction stability summary: (A) Vbeta13.1, NYESO TCR β chain variant 
expression was assessed by intracellular staining followed by flow cytometry analysis.  
 (B) Average VCN of LV-NYESO vector in CD34+ cells after 14 days in culture in media 
promoting myeloid differentiation was assessed by ddPCR. (C) Percentage of LV-NYESO positive 
CFU assessed at different time points post cryopreservation by single colony ddPCR. Each of the 
cell products is color coded as represented in the key. 
 
Table 7: Transduction stability summary 
Test 
FCP 
N=4 
TCP 
0 days 
N=2 
TCP 
30days 
N=5 
TCP 
90 days 
N=2 
TCP 
180 Days 
N=2 
P value 
VCN 0.2±0.2 0.4±0.0 0.3±0.1 0.2±0.1 0.2±0.1 0.80 
Vb13.1 (%) 21.95±7.64 31.95±0.78 26.63±1.2 19.45±1.2 9.52±0.47 0.15 
LV-NYESO 
pos. CFU (%) 
29.2±5.9 40.0±4.2 31.7±9.2 20.5±5.7 25.9±0.1 
0.15 
   The results in the table are mean ± SD.  FCP-Fresh cell product; TCP-thawed cell product. 
  
A. C. B. 
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Table 8: Purity parameter summary 
Test 
FCP 
N=4 
TCP 
0 days 
N=2 
TCP 
30days 
N=5 
TCP 
90 days 
N=2 
TCP 
180 Days 
N=2 
P value 
% CD34+ cells 
(purity) 
95.91±2.68 95.89±0.54 95.60±3.85 96.51±3.42 97.50±0.48 0.95 
Endotoxin 
(EU/kg) 
0.12±0.02 0.14±0.06 0.12±0.04 0.10±0.04 0.10±0.06 0.88 
Mycoplasma 0.32±0.13 0.14±0.10 0.33±0.12 0.37±0.23 0.28±0.08 0.53 
Sterility culture 
(14 days) 
Neg Neg Neg Neg Neg N/A 
Fungal culture 
(21 days) 
Neg Neg Neg Neg Neg N/A 
  The numerical results in the table are mean ± SD. FCP-Fresh cell product; TCP-thawed cell product.   
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12.2. Short-term stability of the cryopreserved cell product after 3, 6, 24 and 48 hours 
post thaw. The original data is summarized in tables 7-11.  The discrepancies in the 
procedures are indicated in each of the tables and summarized in section 13. 
 
Table 9: HD1 Post-thaw stability assessment 
A. After 30 days post-cryopreservation 
Test 
0h 3h 6h 24h 48h 
 RT 4°C RT 4°C RT 4°C RT 4°C 
TNC viability (%) 98.5 97.0 96.9 95.2 97.5 92.4 97.3 82.1 92.9 
CD34+ cell viability 
(%) 
93.82 87.13 92.01 89.29 86.58 84.16 91.39 60.88 84.99 
CD34+ cells/ml 2.7×106 1.8×106 3.6×106 2.1×106 2.2×106 1.7×106 1.7×106 1.4×106 1.7×106 
CD34+ cell recovery 
(%) 
N/A 
67 133 78 81 63 63 52 67 
CFU potential (%) 58±2 50±9 47±6 41±8 43±10 14±1 43±5 5±1 30±6 
 
B. After 90 days post-cryopreservation 
Test 0h 
3h 6h 24h 48h 
RT 4°C RT 4°C RT 4°C RT 4°C 
TNC viability (%) 98.1 98.2 98.2 97.5 97.5 96.1 98.6 89.0 96.8 
CD34+ cell viability 
(%) 
94.35 92.76 92.35 91.52 88.97 86.18 89.49 78.07 89.24 
CD34+ cells/ml 2.8×106 2.6×106 2.8×106 2.6×106 2.6×106 2.9×106 2.5×106 1.2×106 2.0×106 
CD34+ cell recovery 
(%) 
N/A 93 100 93 93 104 89 43 71 
CFU potential (%) 53±13 48±1 55±10 47±8 46±3 16±1 23* 10±3 28±3 * No duplicate plate was counted.  #Discrepancy filed: DIS-01 (see section 13 for details) 
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C. After 180 days post-cryopreservation  
Test 0h 
3h 6h 24h 48h* 
RT 4°C RT 4°C RT 4°C RT 4°C 
TNC viability (%) 98.0 97.3 97.8 97.9 97.9 92.7 97.6 88.1 95.7 
CD34+ cell viability (%) 89.49 90.31 87.13 87.85 87.53 78.57 87.91 N/A N/A 
CD34+ cells/ml 2.5×106 2.4×106 2.6×106 2.1×106 2.1×106 2.3×106 2.4×106 N/A N/A 
CD34+ cell recovery (%) N/A 96 104 84 84 92 96 N/A N/A 
CFU potential (%) 51±11 52±7 53±9 38±3 50±14 35±4 43±6 9±1 26±2 
*CD34 enumeration was not performed after 48h post-thaw (180 days post-cryopreservation).  
Discrepancy filed: DIS-02 (see section 13 for details) 
 
Table 10: HD2 Post-thaw stability assessment 
A. After 30 days post-cryopreservation 
Tests 0h 
3h 6h 24h 48h 
RT 4°C RT 4°C RT 4°C RT 4°C 
TNC viability (%) 98.2 95.2 98.0 96.4 98.9 87.05 92.65 62.4 91.6 
CD34+ cell viability 
(%) 
89.10 85.37 83.25 84.83 82.76 55.92 73.83 15.43 65.97 
CD34+ cells/ml 1.1×106 1.2×106 1.1×106 1.0×106 1.0×106 0.8×106 1.0×106 0.2×106 0.9×106 
CD34+ cell 
recovery (%) 
N/A 109 100 91 91 73 91 18 82 
CFU potential (%) 44±6 37±7 44±5 49±3 42±6 3±1 17±2 0±0 9±3 
 
B. After 90 days post-cryopreservation 
Tests 
0h 3h 6h 24h 48h 
RT 4°C RT 4°C RT 4°C RT 4°C 
TNC viability (%) 96.0 95.5 96.6 93.4 96.5 92.0 96.2 73.3 94.5 
CD34+ cell viability 
(%)* 
88.67 
83.7 82.5 87.5 86.1 74.3 78.5 35.2 70.4 
CD34+ cells/ml* 1.2×106 1.0×106 1.1×106 2.4×106 2.4×106 1.6×106 2.2×106 0.4×106 1.8×106 
CD34+ cell 
recovery (%)* 
N/A 
85 85 185 185 123 169 31 138 
CFU potential (%) 42±5 31±6 36±5 37±7 42±6 8±2 18±0 0.3±0 9±2 
* CD34 enumeration was done in a different facility and was not included in the final summary (Table 
13, Figure 3). Discrepancy filed: DIS-03 (see section 13 for details) 
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Table 11: HD3 Post-thaw stability assessment 
A. After 30 days post-cryopreservation 
Tests 0h 
3h 6h 24h 48h 
RT 4°C RT RT RT RT 4°C RT 
TNC viability 
(%) 
98.9 96.6 96.7 95.8 97.6 92.9 96.7 76.3 95.3 
CD34+ cell 
viability (%)* 
89.02 84.0 79.5 86.5 88.2 69.1 77.7 32.8 55.4 
CD34+ cells/ml* 2.1×106 1.7×106 1.9×106 2.0×106 2.1×106 1.4×106 1.7×106 0.6×106 1.2×106 
CD34+ cell 
recovery (%)* 
N/A 81 90 95 100 67 81 29 57 
CFU potential 
(%) 
47±11 45±3 46±3 43±8 49±10 14±1 27±4 1±1 15±15 
* CD34 enumeration was done in a different facility and was not included in the final summary (Table 
14, Figure 3). Discrepancy filed: DIS-03 (see section 13 for details) 
 
B. After 180 days post-cryopreservation 
Tests 0h 
3h 6h 24h 48h 
RT 4°C RT 4°C RT 4°C RT 4°C 
TNC viability 
(%) 
97.4 98.2 98.1 98.3 98.0 96.3 97.2 88.8 95.9 
CD34+ cell 
viability (%) 
94.05 90.41 90.80 91.32 90.27 82.96 88.57 53.43 81.25 
CD34+ cells/ml 2.8×106 2.2×106 2.2×106 2.3×106 2.4×106 2.1×106 2.6×106 1.4×106 2.3×106 
CD34+ cell 
recovery (%) 
N/A 79 79 82 86 75 93 50 82 
CFU potential 
(%) 
46±3 42±4 42±5 35±4 48±6 13±3 34±4 1±0.5 17±5 
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Table 12: HD4 Post-thaw stability assessment 
After 30 days post-cryopreservation 
Tests 0h 
3h 6h 24h 48h 
RT 4°C RT 4°C RT 4°C RT 4°C 
TNC viability 
(%) 
86.0 86.7 89.4 87.4 90.3 87.1 88.4 77.7 86.1 
CD34 viability 
(%) 
90.73% 88.61 85.67 79.53 80.78 70.62 81.85 26.98 75.43 
CD34+ cells/ml 1.5×106 1.4×106 1.4×106 1.6×106 1.4×106 1.3×106 1.4×106 0.4×106 1.2×106 
CD34+ cell 
recovery (%) 
N/A 93 93 107 93 87 93 27 80 
CFU potential 
(%) 
36±6 33±6 35±4 22±3 26±3 10±1 21±4 0 14±2 
 
 
Table 13: HD5 Post-thaw stability assessment 
After 30 days post-cryopreservation 
Tests 0h 
3h 6h 24h 48h 
RT 4°C RT 4°C RT 4°C RT 4°C 
TNC viability 
(%) 
95.2 93.2 95.05 92.1 94.5 90.3 94.7 83.0 94.4 
CD34 viability 
(%) 
85.12 89.38 87.08 87.04 84.33 70.36 80.14 24.60 75.76 
CD34+ cells/ml 1.5×106 1.6×106 1.5×106 1.5×106 1.3×106 1.1×106 1.3×106 0.4×106 1.3×106 
CD34+ cell 
recovery (%) 
N/A 107 100 100 87 73 87 27 87 
CFU potential 
(%) 
39±4 40±5 42±6 40±6 43±7 6±0 26±5 0±0 12±2 
 
 
The results of the post-thaw stability are summarized in Figure 3 and table 14. Based on the 
results of TNC and CD34 viability, percentage of CD34 recovery and percentage of CFU/cells 
plated, the cell product is stable for up to 6 hours. The clonogenic potential of the thawed cell 
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product and CD34+ cell viability are significantly decreased after 24h storage in both storage 
conditions: ambient temperature (RT) and refrigeration (Figure 3 B and D).  
 
Figure 3: Post-thaw stability of the cell product.  The graphs summarize cumulative data from 
five independently manufactured cell products. The stability parameters of the cell product stored 
at RT or at 4°C were analyzed after 3, 6, 24 and 48h post-thaw and compared to those at 0h. (A) 
Total nucleated cell (TNC) viability of the TCP at different time points after thawing. (B) CD34+ 
cell viability of the FCP at different time points after thawing (N=9). (C) CD34+ cell recovery of the 
FCP at different time points after thawing (N=7). (C) CD34+ cell recovery was calculated by 
dividing the “number of CD34+ cells/ml at 0h” by the “number of cells/ml at 3, 6, 24 and 48h time 
points” and multiplying by 100% (N=7). (D) Clonogeneic potential of the TCP after thawing, as 
measured by %CFU per number of plated cells (N=9). Horizontal bars show averaged values 
(*p<0.05, **p<0.01 and ***p<0.001 when compared to 0h time point, by Tukey-Kramer test) 
   
B. A. 
C. D. 
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Table 14: Summary of the post-thaw cell product stability parameters 
Test 
0h 3h 6h 24h 48h 
 RT 4°C RT 4°C RT 4°C RT 4°C 
TNC Viability (%) 96±4 95±4 96±3 95±3 97±3 92±3 95±3 80±9 94±3 
CD34+ cell viability 
(%) 
91±3 89±2 88±3 87±4 86±3 76±11 85±6 43±25 79±8 
#CD34+ cell recovery 
(%) 
100±0 92±15 101±16 91±10 88±5 81±14 87±11 36±14 78±8 
% CFU/total cell 
plated 
46±7 42±7 44±7 39±8 43±7 13±9 29±10 3±4 18±8 
#The percentage of CD34+ cell recovery was calculated by dividing the “number of CD34+ cells/ml at 
0h” by the “number of cells/ml at 3, 6, 24 and 48h time points” and multiplying by 100%. All the data 
points are compared to the data at 0h. Results are mean ± SD  
 
13. DISCREPANCIES  
A total of three protocol discrepancies occurred during the execution of this qualification study. 
The associated completed DIS forms are included as Attachments 15.1.1-15.1.3 
  
DIS-01: The CFU enumeration assay for HD1, 90 days, 24h post-thaw at 4°C was not counted in 
duplicate due to dried up methylcellulose in one of the plates. As a result, no SD was calculated 
for this time point and this value was omitted from the overall summary (see figure 3 D).  Since 8 
other CFU samples were evaluated at the same time point (for HD2-HD5) and under the same 
conditions, this discrepancy was determined to have no impact on the overall short-term stability 
assessment of the cell product (Attachment 15.1.1). 
 
DIS-02: The CD34+ cell enumeration assay for HD1, 180 days post-cryopreservation, 48h post-
thaw was not performed. The testing core facility performing the CD34+ cell enumeration assay 
was changed from the UCLA Bone Marrow Transplant Unit Flow Cytometry Lab to the UCLA 
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Immunogenetics Center Immune Assessment Core. The new core facility that was used for 
CD34+ enumeration   needed additional samples to validate the assay, therefore, there was not 
enough sample left to perform the CD34+ cell enumeration at the 48h time-point (post thaw). 
Since 6 other samples were assessed for CD34+ cell enumeration at the same time point and 
under the same conditions, this discrepancy was determined to have no impact on the overall 
short-term stability assessment of the cell product (Attachment 15.1.2). 
 
DIS-03: The testing core facility performing the CD34+ cell enumeration assay was changed from 
the UCLA Bone Marrow Transplant Unit Flow Cytometry Lab to the UCLA Immunogenetics 
Center Immune Assessment Core. During the transition period, the samples for HD2, 90 days 
post-cryopreservation and HD3 30 days post-cryopreservation at 3, 6, 24 and 48h post-thaw were 
performed “in house”. Due to differences in the analysis methodology, the CD34 enumeration 
results from those time points were not included in the final summary (see Figure 3B and 3C). 
Since 7 other samples were assessed for CD34+ cell enumeration at the same time points (6 
samples for the 48h time point) and under the same conditions, this discrepancy was determined 
to have no impact on the overall short term stability assessment of the cell product (Attachment 
15.1.3). 
14. CONCLUSIONS  
The current report summarizes the results of the long and short-term stability studies for 
cryopreserved LV-NYESO TCR/sr39TK PBSC product. 
These results show that the cell product is stable for at least 180 days after cryopreservation 
and storage in a vapor phase of liquid nitrogen. The short-term stability results show that the 
cell product is stable up to 6 hours post-thaw.   
15.  ATTACHMENTS  
15.1. Discrepancy Evaluation Forms: 
15.1.1. DIS-01  
15.1.2. DIS-02  
15.1.3. DIS-03  
Stability evaluation of PBSC transduced with LV-optNYESO 
TCR/sr39TK     
Report  AR-CIRM-17-002-R Version: 01 Effective Date:_______________ Page 28 of 28   
15.2. Discrepancy log 
 
15.3. AR-CIRM-17-002-P ver.01: Stability evaluation of PBSC transduced with LV-optNYESO 
TCR/sr39TK.     
